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 Executive Summary 
 
Executive Summary 
This report looks at the costs and benefits associated with young people’s drug 
and alcohol treatment. 
There were approximately 24,000 young people who received specialist drug and 
alcohol treatment in the UK in 2008-09. This is defined as “a care planned 
medical, psychosocial or specialist harm reduction intervention”. As set out in 
the Drug Strategy 2010 such treatment is aimed at preventing escalation of use or 
harm and should “respond incrementally to the risks in terms of drug use, 
vulnerability and, particularly, age.” Most of these young people were treated 
primarily for alcohol (37%) or cannabis (53%) misuse, with the remaining 10% 
misusing Class A drugs, including heroin and crack. Apart from using drugs and 
alcohol, these young people had experienced a range of other problems, 
including involvement in crime (shoplifting, theft, assault); being NEET (not in 
education, employment or training); or housing problems. 
The National Treatment Agency (NTA) has oversight of young people’s 
specialist substance misuse services and systematically collects information on 
those young people accessing them. This information includes data on young 
people’s characteristics and, for most 16 and 17 year olds, a range of outcomes 
comparing treatment start and exit (such as crime, health, housing and 
education). We have drawn upon this data and the evidence from a range of 
academic studies and policy reports to assess the cost-effectiveness of young 
people’s specialist drug and alcohol treatment in the UK. 
Throughout the report the term ‘young people’ is taken to refer to those aged 
under 18 unless stated otherwise. However, as noted much of the evidence base 
from the UK and abroad applies to those aged 16 or 17. The impact of this is 
discussed in the methodology section. 
Our approach 
There are two main elements of our study: 
à Costs: Understanding the amount that is spent in total and per person 
on specialist drug and alcohol services for young people in 2008-09. 
à Benefits: Estimating and valuing the benefits of young people’s drug 
and alcohol treatment – measured as a reduction in the economic and 
social costs of drug and alcohol misuse. 
While measuring the costs of treatment is relatively straightforward, assessing the 
benefits associated with treatment is more complicated. First, we need to 
establish a counterfactual, i.e. what would have happened to these young people 
in the absence of treatment. There is significant evidence that many of these 
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young people would, in the absence of treatment, impose significant economic 
and social costs on society. These costs can be split into: 
• Immediate costs – the cost of crime committed by young people misusing 
drugs, the NHS costs associated with treatment of drug and alcohol-related 
conditions affecting young people, and the cost of drug and alcohol related 
deaths for young people1; and 
• Long-term costs – the costs incurred if young substance misusers become 
problematic drug users (PDUs) or problematic alcohol users as adults. If this 
happens, the costs imposed on society are likely to increase further as adult 
PDUs and problematic alcohol users tend to commit more frequent and 
serious crimes, impose higher costs on the NHS, are more likely to die 
prematurely and have high unemployment rates. Finally, those young people 
who do not become PDUs or problematic alcohol users as adults might still 
incur long term costs. Indeed, young substance misusers are more likely to 
be NEET (not in education, employment or training) and leave school 
without qualifications. This too has a cost, in terms of lower wages and 
poorer employment prospects. 
We rely on NTA data from the National Drug Treatment Monitoring System 
(“NDTMS”) and the associated Treatment Outcomes Profile data (“TOP”) and a 
range of academic studies and policy reports to estimate these counterfactual 
costs. 
We estimate that the immediate counterfactual cost of crime committed by 
young people misusing drugs and alcohol is just under £100m per year. This 
equates to an annual cost of crime per young drug and alcohol user of around 
£4,000 per person per year in the absence of treatment. These costs appear to be 
driven by a relatively small number of the young people misusing drugs or 
alcohol, with the majority reporting no offending. The annual counterfactual 
health care cost of young people’s drug and alcohol misuse is around £4.3m per 
year, or £179 per person per year. Within this, the counterfactual cost of drug 
and alcohol related death accounts for £4.2m per year; the remainder is the cost 
of drug and alcohol related illness. 
In order to estimate the long term counterfactual costs of adult substance misuse 
for young people in treatment, we look at three types of adult substance misuse: 
à adult alcohol misuse; 
à adult problematic drug use (PDU); and 
                                                 
1 There may be other type of immediate costs (e.g. teenage pregnancies) which we do not quantify in this 
study. 
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à adult non-problematic drug use (non-PDU).2 
It is likely that young people’s substance misuse contributes to further costs, 
including those associated with children’s services, and particularly the costs of 
being taken into care. However, it was not possible to isolate the proportion of 
these costs attributable to substance misuse and so these were not factored into 
the overall cost figures. Throughout the report we have taken a cautious 
approach to constructing cost and benefit figures to ensure that the final 
calculations provide a robust lower estimate of any projected savings. 
In Table 1 below, we summarise the costs associated with adult substance 
misuse – these are the costs of crime, poor health, premature death and lost 
output due to absenteeism and low employment levels. These costs are high and 
vary between £21,300 - £45,100 per year for non-problematic adult drug users, 
£173,090 - £238,397 per year for adult alcohol abusers, and £550,388 - £958,848 
per year for problematic adult drug users.3 
                                                 
2 Throughout this report, the term problematic drug user (“PDU”) refers to clients citing opiates, crack 
cocaine, or both as any of their presenting substances. Non-problematic drug users (“non-PDUs”) are 
clients using illegal drugs other than opiates or crack when presenting for treatment. It should be noted 
here that even non-problematic drug use can impose considerable economic and social costs to society. 
Alcohol misuse in this report includes not just dependent drinking, but also harmful alcohol use (defined 
as drinking over the recommended weekly amount and experiencing health problems directly related to 
alcohol) and is consistent with our estimates of the costs of adult alcohol misuse. 
3 The cost estimates reported for adult problematic drug users are broadly consistent with previous estimates 
made by NICE, and subsequently adopted by the NTA in their recent analysis of the value for money of 
adult drug treatment. In particular, these studies estimate a lifetime crime cost of £445,000 for an injecting 
drug user, and a lifetime health cost of £35,000. Although at the lower end of our estimates of the lifetime 
cost of an adult PDU, these studies do not include costs such as lower productivity or other lost output 
and are therefore broadly in line with the estimates shown here. 
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Table 1. Lifetime costs of adult substance misuse 
Type of adult 
substance 
misuse 
Study Annual 
cost 
Discounted 
lifetime cost 
Range of 
discounted 
costs 
The Societal Cost of Alcohol Misuse in 
Scotland for 2007 
£16,207 £238,397 
Alcohol misuse: How much does it cost? 
(First estimate) 
£11,767 £173,090 Adult alcohol 
abuse 
Alcohol misuse: How much does it cost? 
(Second estimate) 
£12,737 £187,363 
£173,090 to 
£238,397 
The economic and social costs of Class A 
drug use in England and Wales, 2000 
(High estimate) 
£61,109 £898,909 
The economic and social costs of Class A 
drug use in England and Wales, 2000 
(Medium estimate) 
£52,224 £768,214 
The economic and social costs of Class A 
drug use in England and Wales, 2000 
(Low estimate) 
£37,416 £550,388 
Adult 
problematic 
drug use 
Assessing the scale and impact of illicit 
drug markets in Scotland 
£65,184 £958,848 
£550,388 to 
£958,848 
Adult non-
problematic 
drug use 
RAND prevention cost effectiveness study   £21,300 to 
£45,100 
Source: Frontier calculations based on the Home Office and RAND publications 
However, not all young substance misusers will become problematic adult 
substance users, or experience other wider problems, even if not treated. Existing 
academic studies suggest that between 30% and 40% of moderate/heavy teenage 
alcohol and cannabis users would develop drug/ alcohol misuse problems as 
adults while the remaining 60%-70% would experience natural remission (even if 
not treated). The proportion is however higher for teenage Class A drug users 
(up to 95% of teenage Class A drug users continue to use drugs in adulthood). 
We combine the lifetime costs of adult substance misuse with the probabilities 
that young people currently in treatment would have become adult problematic 
and non-problematic drug users in the absence of treatment. The results of the 
counterfactual cost calculations are presented in Table 2 below. 
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Table 2. Total lifetime counterfactual costs attributable to young substance 
misusers who access treatment 
 Long-term counterfactual costs 
Total counterfactual costs £1.1 billion - £2.2 billion 
Total counterfactual costs (per person) £46,145 - £91,964 
Source: Frontier analysis based on the NDTMS/TOP, Hser et al. (2008), Filmore (1975) and Patton et al. 
(2006) 
It is worth noting that these average costs are lower than the unit costs of being a 
PDU or a problematic alcohol user. This is because some young people (between 
56% and 64% of the sample) are expected to experience natural remission (i.e. 
reduce or halt their drug or alcohol use as they move out of adolescence) and, 
therefore, not incur these costs in the future. In addition, 17.5% of the sample 
are expected to become non-PDUs (if not treated), with the costs of non-PDU 
being somewhat lower – between £21,300 and £45,100 over a 20 year period. 
The final element of long term counterfactual costs that we have considered is 
the cost associated with being NEET. This leads to poorer educational 
attainment and labour market outcomes in later life. Recent academic literature 
has valued the lifetime cost of educational underachievement and poor 
employment prospects at between £92,000 and £356,000 per person (expressed 
as a net present value4).  
After the counterfactual costs are established, we can estimate the benefits of 
treatment. As a result of treatment, most young people reduce their drug and 
alcohol consumption, commit fewer crimes and report improved wellbeing. The 
likelihood of their becoming PDUs or problematic alcohol users as adults also 
decreases. Therefore, some of the costs that these young people would have 
imposed on society if not treated are now averted. We estimate these reductions 
in the counterfactual costs (i.e. the benefits of treatment) and compare them 
against the cost of treatment. Throughout this report, all of the immediate and 
long term counterfactual costs and future benefits have been appropriately 
discounted, and are reported in terms of their net present value. Our findings are 
discussed in detail below. 
                                                 
4 The net present value (“NPV”) is the total value now of a stream of future costs and benefits. The value of 
each future cost or benefit is discounted, as the value of a payment made in a future period is lower than if 
the same nominal amount had been paid in the current period. 
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Costs of treatment 
The total amount spent on local services for young substance misusers in 2008-
09 was £62.2m. Around 40% of this funding came from the Young Person’s 
Pooled Treatment Budget. The remainder was provided through Area Based 
Grants, Home Office funding for Youth Offending Teams or Youth Justice 
Board spending via the secure estate. 
It is not possible to entirely distinguish between funding that is allocated for drug 
and alcohol treatment and funding that is allocated to provide drug information 
and preventative advice. However, despite these limitations, we believe that the 
figure of £62.2m is a good estimate of the total cost of providing treatment 
services for young people in 2008-09. 
Benefits of treatment 
Both the immediate and long term benefits of treatment describe the economic 
and social costs that are avoided as a result of getting people into specialist drug 
and alcohol treatment. The immediate benefits of treatment are lower levels of 
drug and alcohol related crime, and fewer drug and alcohol related inpatient 
admissions and deaths. The long term benefits of treatment are a lower 
likelihood (and therefore lower expected cost) of young people developing 
substance misuse problems as adults, and improved educational attainment and 
labour market outcomes. 
Immediate benefits 
Data provided by the NTA indicates that the potential immediate benefit of drug 
and alcohol treatment could be up to a 55-65% reduction in offending by young 
people receiving treatment. This equates to a £59.3m net annual saving as a result 
of treatment. 
Our analysis also shows around a 40% drop in the estimated number of drug and 
alcohol related deaths and hospital admissions post-treatment. This equates to a 
benefit of around £1.8m per year in terms of the NHS and wider social costs that 
can be avoided. 
The immediate benefit from reduced crime alone appears to be sufficiently large 
to suggest a positive net benefit of drug and alcohol treatment for young people. 
Even assuming no long term benefits or immediate health benefits, we calculate 
that in order for young people’s treatment to be cost effective, the required 
reduction in the immediate amount of crime committed by young people is just 
32%. 
It should be noted that the proportion of young people in treatment who are 
offending appears to be low. However, these rates should be expected to under-
report levels of offending as young people may be reluctant to admit to 
offending behaviour. In addition, those who do offend appear to be fairly 
prolific, contributing to the costs identified within this report. By treatment exit, 
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the amount of self-reported offending committed by young people has fallen on 
average by 55-65%. 
Long term benefits 
Unlike the immediate benefits of treatment, the long-term benefits are very 
difficult to assess. The NDTMS/TOP data includes information on a range of 
outcomes immediately after treatment, such as substance use, education, 
employment, crime and health. These immediate impacts, however, cannot be 
easily ‘translated’ into long-term effects.  
To assess the long term benefits of fewer adult substance misuse problems, we 
look at the re-presentation rates for young people four years after treatment. 
These are: 
à 40% for Class A drug users (comparable to adult PDUs); 
à 16% for alcohol users; 
à 17% for cannabis users. 
Compared to long-term substance misuse rates expected without treatment 
(37%-44%), treatment is effective for many young people. That is to say that 
many young people who would otherwise be expected to escalate their drug or 
alcohol use and develop further problems appear to have effectively reduced or 
halted their misuse for up to four years after treatment (judged by NTA re-
presentation data). 
However, we need to exercise caution when using these re-presentation rates as a 
proxy for the treatment’s effectiveness. This is because some young people may 
relapse after the period covered by the re-presentation data. Others may have 
developed problematic drug or alcohol use again, but without re-accessing 
treatment. Therefore, in our hypothetical scenarios below, we adopt a 
conservative approach and use slightly lower effectiveness rates - 7% and 10% - 
than the 4 year re-presentation rates of 20% reported by the NTA. 
In the absence of concrete evidence on long-term effectiveness of young people’s 
treatment, we adopt a scenario-based approach. We find that if the number of 
those who are likely to develop substance misuse problems as adults is reduced 
by 2.8% - 5.6%, the long-term benefits of treatment would offset the cost of 
treatment (assuming that the immediate benefits are excluded from this analysis). 
Moreover, with a slightly higher reduction in the number of those who would 
have long-term drug related problems – 7%-10% reduction – the long-term 
benefits of treatment would exceed the cost of treatment. More specifically: 
• a 7% reduction in the number of young people who are likely to become 
adult substance misusers in their lifetime would generate £15.5 million - 
£92.6 million net benefits; and 
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• a 10% reduction in the number of young people who are likely to become 
adult substance misusers in their lifetime would generate £48.8 million – 
£159.0 million net benefits. 
If these reductions (7%-10%) are achieved, the long-term net benefits of 
treatment would be high – up to £159 million.  
To estimate the long-term benefits of improved educational outcomes, we have 
modelled the effect of treatment on the proportion of young people who are not 
in education, employment in training. When entering treatment, 45% of young 
people in our sample are NEET, compared to 9% of the wider population. Data 
from the NTA however indicates that treatment could potentially reduce the 
proportion of young people that are NEET by 6.5%. 
Using estimates of the lifetime cost of being NEET, a 6.5% reduction in the 
proportion that are NEET leads to a total lifetime benefit for young people in 
our sample of £159m, equivalent to £6,590 per person. If the reduction in the 
NEET percentage was just 5%, this would still lead to significant benefits 
totalling £121m. On the other hand, a 10% reduction in the NEET percentage 
would generate £242m of benefits, more than £10,080 per person. This only 
takes into account changes in NEET status by the time of treatment exit. It does 
not include any impact of treatment in supporting young people to be ready for 
employment or education and may therefore underestimate the benefits of 
treatment in this area. 
We sought to assess the costs faced by wider children’s services, including costs 
of children being taken into care. However, it is difficult to identify the 
proportion of such costs that could be directly attributed to young people’s 
substance misuse. As such, and in the interests of robust estimates we have not 
included such costs within this analysis. 
Net benefits of treatment 
Table 3 summarises our results and brings together both estimates of immediate 
and long-term benefits. All of the immediate and long term benefits in this report 
have been appropriately discounted and are expressed in NPV terms. 
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Table 3. Summary of costs and benefits 
Benefits Per 
person 
Per year for 
all young 
people in 
treatment in 
2008-09 
Across a lifetime of 
substance misuse 
for all young people 
in treatment in 
2008-09 
Ratio of 
benefits to 
costs 
Total costs per year  £62.2m  
Immediate benefits £2,539 £61.1m £120.1m £1.93 
Crime £2,464 £59.3m £116.5m £1.87 
Health £74 £1.8m £3.5m £0.06 
Long-term benefits - - £170.0m - £401.5m £2.73 – £6.45
Education and 
employment 
- - £121.2 - £242.5m £1.95 - £3.90 
Adult problematic 
substance misuse 
- - £48.8m – £159.0m £0.78 – £2.56 
Total benefits - - £290.1m - £521.6m £4.66 – £8.38
Source: Frontier analysis 
Throughout this report, we highlight several key limitations of our analysis, 
particularly relating to the practical or conceptual difficulties in identifying and 
quantifying the benefits associated with young people’s drug treatment. However, 
despite these limitations, our results provide a robust yet conservative estimate of 
the benefit of young people’s drug treatment. 
In particular, the results shown in Table 3 are robust to changes in the 
assumptions surrounding both the immediate and long-term benefits of 
treatment. When compiling figures we have tended to use the upper estimate of 
costs associated with treatment and the lower estimate of any benefits. Finally, to 
the extent we have been unable to capture certain benefits in our analysis, our 
results again represent a conservative estimate of total benefits. 
Overall, the study has shown that the immediate and long-term benefits of 
specialist substance misuse treatment for young people are likely to significantly 
outweigh the cost of providing this treatment. In particular, we have estimated a 
benefit of £4.66-£8.38 for every £1 spent on young people’s drug and alcohol 
treatment. Furthermore, our central case estimates are based on a conservative 
set of assumptions. Therefore, the benefit of specialist drug and alcohol 
treatment for young people may be larger than we report here. 
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1 Introduction 
The Department for Education (“DfE”) appointed Frontier Economics to 
undertake a cost benefit analysis of drug policy relating to young people. This 
project is an element of a broader piece of work being carried out by the Centre 
for Analysis of Youth Transitions. 
There are two types of policy relating to drug and alcohol misuse by young 
people: prevention and communication policies; and treatment policies. 
Following initial discussions with the Department for Education, we have 
narrowed the focus of our work to cover young people’s drug and alcohol 
treatment. This has allowed us to focus on a specific group of young people in 
need of treatment. 
The central question posed by the Department for Education was therefore: 
what are the costs and benefits of drug and alcohol treatment for young people? 
The remainder of this report presents the main findings of our work. The report 
is structured as follows: 
à Section 2 describes the background to young people’s drug and alcohol 
treatment and previous studies in this area; 
à Section 3 sets out in more detail the approach we have taken and the 
data we have used; 
à Section 4 sets out the treatment costs relating to drug and alcohol 
misuse by young people; 
à Section 5 discusses the likely outcomes for young people who do not 
receive treatment and the cost of these outcomes – the counterfactual; 
à Section 6 describes the impact of treatment on these outcomes, 
quantifies the resulting benefits, and discusses the key drivers of the 
results; and  
à Section 7 discusses the implications of these results and concludes. 
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2 Background 
In this section, we first describe the scope of our work and the particular aspects 
of young people’s drug policy that we have focussed on in this report. We then 
briefly explain the development of drug and alcohol treatment in the UK and 
summarise some of the key existing literature on the effectiveness of drug and 
alcohol treatment. Much of the available literature relates to adult misuse. Given 
the divergent patterns of substance misuse and treatment responses between 
adults and young people we need to use this literature cautiously. We therefore 
identify in this section where research specifically relates to adolescent drug or 
alcohol treatment. 
2.1 Scope of the study 
Young people’s drug policy covers many areas, encompassing education 
initiatives in schools, the criminal justice system, specialist treatment services, 
social care, and other elements of children’s services. These policy areas tend to 
overlap as young people who misuse drugs and alcohol typically face a number of 
other problems such as exclusion from school, family breakdown etc. It is 
therefore extremely difficult to identify the relative contribution of each 
individual programme or policy initiative to improvements in outcomes for 
young people. Similarly, identifying the relative contribution of prevention 
initiatives and treatment policies to lower drug and alcohol misuse by young 
people is likely to be difficult. 
This report therefore focuses specifically on the costs and benefits of one 
element of young people’s drug policy in isolation. We do not comment on the 
relative cost effectiveness of treatment policies versus prevention policies or on 
the relative cost-effectiveness of one programme versus another. 
2.1.1 Treatment or prevention 
The Department of Health group treatment into four tiers according to the scale 
of the intervention that is required5, as shown in Table 4. 
                                                 
5 Department of Health (2002) “Models of Care for Treatment of Adult Drug Misusers” 
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Table 4. Tiers of treatment 
Tier Description 
Tier 1 Interventions from general healthcare and other services that are not 
specialist drugs services, for example hospital A&E departments, 
pharmacies, GPs, antenatal wards and social care agencies. Tier 1 services 
offer facilities such as information and advice, screening for drug misuse 
and referral to specialist drugs services. 
Tier 2 Open-access drug treatment (such as drop-in services) that does not 
always need a care plan. Tier 2 covers things like triage assessment, 
advice and information and harm reduction given by specialist drug 
treatment services. 
Tier 3 Drug treatment in the community with regular sessions to attend, 
undertaken as part of a care plan. Prescribing, structured day programmes 
and structured psychosocial interventions (counselling, therapy etc) are 
always Tier 3. Advice, information and harm reduction can be Tier 3 if they 
are part of a care plan. 
Tier 4 Residential drug treatment – inpatient treatment and residential 
rehabilitation. Treatment should include arrangements for further treatment 
or aftercare for clients finishing treatment and returning to the community. 
Source: NTA 
However, young people’s patterns of substance misuse and the treatment 
approaches required vary considerably from those associated with adults. 
Substance misuse interventions for young people tend to be categorised as 
universal (typically education and communication programmes), targeted 
(including early intervention for at-risk groups such as young offenders or looked 
after children), and specialist (for those who have already developed drug or 
alcohol misuse and who require a care-planned structured package of support). 
We have restricted our study to those young people receiving specialist support 
in 2008 -09. 
The vast majority of young people accessing specialist treatment need and receive 
counselling, sometimes alongside their families to address the underlying causes 
and consequences of substance misuse. Such psychosocial interventions are the 
most common form of support accessed by under-18s. A small number of young 
people may need more intensive support, including a package of care that 
combines support from a specialist children’s home or foster care placement with 
substance misuse services. A very small number may need pharmacological 
interventions. 
Many young people benefit from general interventions and open-access drug and 
alcohol treatment or preventative advice (i.e. local prevention, education, or early 
 15 
 
 Background 
 
intervention services). However, these individuals are not captured in the data we 
have used for this analysis as the treatment they receive does not form part of a 
structured care plan. Little is known about the circumstances and characteristics 
of those accessing targeted services. Because of this difficulty, the benefits of 
treatment for the group of young people receiving non-specialist interventions 
have not been captured in our study.  
2.1.2 Limitations of our work 
In this report, we have presented our best estimates of the likely costs and 
benefits associated with young people’s drug and alcohol treatment. The costs 
and benefits described are based on an extensive examination of the available 
evidence and provide reasonable estimates of the likely impact of young people’s 
drug and alcohol treatment. 
However, as with any study that requires an assessment of what would have 
happened in the absence of an intervention (i.e. the counterfactual), there are 
some key limitations of our work. These include: 
à conceptual limitations to what our work can and cannot demonstrate; 
and 
à data limitations where evidence is missing, incomplete, or not 
sufficiently robust to provide a definite answer. 
Because of these, we have not been able to provide a definitive figure for the 
financial benefits of young people’s drug and alcohol treatment. Instead, our 
results are presented in two ways: first as a range of potential benefits, depending 
on the particular assumptions used; and second in terms of the required impact 
that young people’s drug and alcohol treatment would need to have in order for 
the treatment to be cost effective. 
Conceptual limitations 
Cost benefit studies typically compare a group who are affected by a certain 
policy (i.e. those who receive treatment) with a control group who are unaffected 
by the policy (i.e. those who do not receive treatment). A key source of 
uncertainty in this project centres on how to define an appropriate counterfactual 
for young people who do not receive treatment.  
A common problem highlighted in previous reviews of cost effectiveness and 
outcome studies of drug treatment services is that there is no control group 
which can be used to form this counterfactual6. Ideally, individuals should be 
randomly assigned to both the treatment group and the counterfactual in order to 
prevent ‘self-selection bias’ in the results. The most appropriate control group in 
                                                 
6 National Audit Office (2010) “Tackling problem drug use” 
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our study are drug users with an identified treatment need who do not receive 
treatment. However, there are obvious ethical issues which prevent such an 
approach in this case. Having established a treatment need, treatment providers 
have an obligation to treat these individuals, rather than monitor them as part of 
a control group. 
As a result, no single data source can compare the outcomes for those receiving 
treatment with a control group that does not receive treatment. Developing an 
appropriate counterfactual must necessarily involve some assumptions. This in 
turn introduces some uncertainty over what would have happened to these 
people in the absence of treatment. 
Data limitations 
This study has been further limited by the lack of detailed data and the absence 
of robust evidence that can be used to evaluate the likely effect of treatment.  
Our approach was to compare the behaviour and characteristics of young people 
when entering treatment with the characteristics and behaviour of the same 
group of young people after they left treatment. The observed change in 
outcomes could then be one potential proxy measure for the immediate or short-
term effect of treatment. 
In practice, the available data on young people before and after treatment only 
covers a limited sample of those in treatment, and a specific age range (16 and 17 
year olds). We have used this data to assess some of the impacts of treatment, 
and the resulting analysis has some important caveats surrounding how 
representative the data is of the population of young people in treatment. 
Furthermore, the data comparing outcomes before and after treatment does not 
control for other changes in the lives of young people which may have affected 
their health or their involvement in criminal activities over the time they are in 
treatment. We are therefore unable to distinguish from the data the impact that 
treatment has on outcomes compared to the impact of other factors on changes 
in outcomes before and after treatment. 
We began our study with the intention of using a measure of young people’s re-
presentation into the adult treatment system as a measure of treatment 
effectiveness. However, this information provides only a partial picture of 
treatment effectiveness. It is only available for a limited time period and it does 
not, by definition, capture details of young people who go to develop further 
problematic substance misuse but do not re-enter the treatment system. We have 
therefore sought alternative sources of information on the long-term impact of 
drug and alcohol treatment for young people to develop a more robust picture of 
costs and benefits. 
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2.2 Background to young people’s treatment 
Before reviewing previous studies on the cost effectiveness of treatment, it is 
worth outlining how drug policy has developed in the UK over the past 15 years, 
and the role that treatment plays. We begin by describing young people’s 
treatment, looking at some of the differences between adult and young people’s 
treatment. Next we summarise how drug and alcohol treatment has developed 
since the NTA was set up in 2001. Finally we discuss some of the evidence on 
the number of young people using drugs. 
2.2.1 Description of young people’s treatment 
The priority for adult drug treatment has largely been to reduce the number of 
problematic drug users (defined as users of opiates and/or crack cocaine). These 
drug users cause the most harm to society and according to a report by Godfrey 
et al. (2002)7 account for 99% of the costs to society of Class A drug use. The 
same report by Godfrey identified the estimated annual cost to society of Class A 
drug use as £15.3bn (in 2001 prices). There are an estimated 330,000 adult 
problem drug users in total, but only 166,000 problem drug users are engaged in 
effective treatment in the community8. There are potentially large savings to be 
made by getting more adult problem drug users into effective treatment or by 
preventing young people from becoming problem drug users as adults. 
Young people’s drug and alcohol treatment is very different to adult drug 
treatment. Few young people would fall into the category of problem drug users. 
Just 2% of young people who enter treatment do so with problems with opiates 
or crack9. Young drug and alcohol users also differ from adults in that they will 
typically not have used drugs for sufficiently long so as to develop dependencies. 
This then affects the type of treatment typically provided to young people. As 
shown in Table 5, the types of specialist intervention required to treat young 
people are more likely to involve psychosocial interventions10 and harm 
reduction measures11, rather than specialist pharmacological interventions (such 
as methadone prescribing) which are more appropriate for treating dependent 
adults. 
                                                 
7 Godfrey et al. (2002) “The economic and social costs of Class A drug use in England and Wales, 2000” 
Home Office Research Study 249 
8 NAO estimate 
9 See Table 10. 
10 Psychosocial interventions are non-pharmacological interventions typically involving structured 
counselling, motivational enhancement, case management, care-coordination, psychotherapy, and relapse 
prevention. The intention is to encourage behavioural and emotional change, the support of lifestyle 
adjustments and the enhancement of coping skills. 
11 Harm reduction includes services to manage injecting behaviour (e.g. needle exchange, advice on injecting, 
access to appropriate testing), advice to prevent overdose, and reducing substance misuse related injury. 
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Table 5. Interventions received by young people in 2008-09 
Type of intervention Proportion of total 
interventions 
Psychosocial only 51% 
Harm reduction only 12% 
Family work only 1% 
Specialist pharmacological only 0% 
Access to residential treatment only 0% 
Psychosocial & family work 1% 
Psychosocial & pharmacological 0% 
Psychosocial & family work & pharmacological 0% 
Psychosocial & family work & harm reduction 2% 
Psychosocial & harm reduction 19% 
Psychosocial & harm reduction & pharmacological 0% 
Other interventions or combinations 9% 
No named interventions 4% 
Source: NTA "Substance misuse among young people: The data for 2008-09 
Since 2003, the NTA began collecting quantitative information on young people 
in treatment via the National Drug Treatment Monitoring System (“NDTMS”). 
This records the drugs used by people in treatment, and a number of other 
characteristics of those receiving treatment. In 2007, a further element to the 
NDTMS was introduced to help monitor the outcomes of treatment, known as 
the Treatment Outcomes Profile (“TOP”). The TOP asks about the 
characteristics and behaviour of young people when they enter treatment, when 
they leave treatment and at selected intervals during their treatment. The 
NDTMS and TOP data are useful in exploring both the characteristics of young 
people entering treatment and the effectiveness of treatment for these young 
people. 
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2.2.2 The extent of drug and alcohol use among young people 
The British Crime Survey provides a measure of the extent of drug use by young 
people. In 2008-09, 22% of 16-19 year olds reported that they had used illicit 
drugs in the past year, and 7% of 16-19 year olds had used a Class A drug in the 
past year. Cannabis was the most commonly used drug, with 18% of 16-19 year 
olds reporting use in the past year. The next most commonly used was cocaine 
powder, used by 5% of 16-19 year olds in the past year.  
The proportion of people aged 16-19 who used illicit drugs in the past year 
declined steadily from 1998 to 2007-08, before increasing again slightly in 2008-
09. A similar pattern can be seen for Class A drug use. This pattern may have 
emerged for a number of reasons, with increased effectiveness or availability of 
drug treatment just one of many potential explanations for the observed trend. 
The NHS Information Centre produces an annual report on drug and alcohol 
use by 11-15 year olds12. The proportion of 11-15 year olds who have taken drugs 
in the last year has decreased from over 20% in 2001, to 14.8% in 2009. A large 
part of this decrease has come through a reduction in the proportion of young 
people using cannabis, which fell from 13.4% in 2001 to 8.9% in 2009. 
As shown in Table 6, 3.6% of young people aged 11-15 have used any Class A 
drug in the last year. However, this proportion is much higher for 15 year olds 
alone, where 8.9% used a Class A drug last year. Cocaine, crack and heroin use 
similarly becomes more widespread at age 15. 
                                                 
12 NHS Information Centre “Smoking, drinking and drug use among young people in England in 2009” 
Table 2.7c 
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Table 6. Percentage of pupils aged 11-15 who have taken individual drugs in the 
last year, by age 
Age Any 
drug 
Any Class A 
drug 
Cannabis Cocaine Crack Heroin 
11 4.5% 0.8% 0.5% 0.2% 0.3% 0.1% 
12 6.6% 0.8% 1.7% 0.2% 0.3% 0.2% 
13 9.8% 2.3% 4.0% 0.4% 0.4% 0.3% 
14 18.6% 3.6% 12.0% 1.5% 0.7% 0.3% 
15 29.7% 8.9% 22.8% 3.4% 1.4% 1.1% 
Total 14.8% 3.6% 8.9% 1.2% 0.6% 0.4% 
Source: NHS Information Centre “Smoking, drinking and drug use among young people in England in 
2009” Table 2.7c 
We are unable to combine these two data sources to establish a typical profile of 
drug use by young people. The evidence does suggest however that drug use by 
young people is already established by the time they are 15. Aged 16-19, the 
proportion of people using drugs in the last year then appears to stabilise or even 
decline. We cannot be sure whether this is due to changes in the way the data on 
drug use is collected or reported across the available data sources or whether this 
represents a real decline in use by 16-19 year olds. 
The NHS Information Centre reports in 2008 that 52% of pupils aged 11-15 had 
ever had an alcoholic drink, and that 18% had drank alcohol in the past week. 
This varies widely by age: 16% of 11 year olds had ever had an alcoholic drink 
(3% in the last week); compared to 81% of 15 year olds (38% in the last week). 
Of those pupils that drank alcohol in the past week, the mean number of units 
consumed was 14.6 units and the median number of units consumed was 8.5 
units. 
2.3 Previous studies 
There is good evidence in the UK of the cost-effectiveness of adult drug 
treatment. However, there has been little or no quantitative evaluation of the 
cost-effectiveness of treatment for young people. The available evidence on the 
effectiveness of drug and alcohol treatment for young people focuses primarily 
on the US. In the UK, policy evaluations have either focused on adult drug 
treatment alone or have not looked at the benefits of treatment directly. 
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There have been several attempts in the past to measure the annual cost of drug 
and alcohol misuse to society. We discuss some of these attempts at length when 
estimating the cost of adult problem substance misuse. The aim of this report 
however is not to quantify the economic and social cost of drug and alcohol use 
by young people, rather to evaluate the cost-effectiveness of treatment policies 
designed to reduce this economic and social cost. This section therefore focuses 
on studies that measure cost-effectiveness of treatment only. 
Below, we describe some of the previous attempts to measure the cost-
effectiveness of treatment. This includes reviews of NTORS and DTORS, two 
major studies of adult treatment in the UK. We also discuss some of the 
international evidence on the effectiveness of treatment programmes. As noted 
above, we have broadened our literature review to include evaluations of adult 
treatment programmes, although we acknowledge that the differences between 
adult and adolescent substance misuse mean that findings from these evaluations 
need to be applied to the current project cautiously. 
2.3.1 Evidence from the UK 
NTORS 
Following the 1995 White Paper on drugs13, a government taskforce was 
appointed to help measure the effectiveness of treatment services. As part of this, 
the taskforce commissioned the National Treatment Outcome Research Study 
(“NTORS”) – the first national prospective study of treatment outcomes for 
drug misusers in the UK. The NTORS study was a longitudinal cohort study of 
1,075 adults starting a new drug-related treatment episode at one of 54 
participating residential and community treatment agencies from March-July 
1995. This was primarily an adult study – the average age of the cohort studied 
was 29.3 years, with a range of 16-58 years14. 
The NTORS study looked at a subset of four treatment types, selected because 
they were representative of the main types of treatment programme in the UK. 
These treatments included inpatient drug dependence units; residential 
rehabilitation agencies (both in residential settings); methadone maintenance 
programmes; and methadone reduction programmes (in a community setting). 
The study focussed on a limited number of drugs: heroin; non-prescribed 
methadone; crack cocaine; powder cocaine; amphetamines; and benzodiazepines. 
The study also asked about alcohol use before and after treatment. No questions 
were asked about the level of cannabis use. The study concentrates more on 
treatment for Class A drug users, and is therefore less applicable to young people, 
                                                 
13 Government White Paper (1995) “Tackling Drugs Together” 
14 Gossop et al. (1998) “Substance use, health and social problems of service users at 54 drug treatment 
agencies” 
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a large proportion of whom receive treatment for cannabis or alcohol misuse 
problems. 
Participants in the NTORS study were interviewed three times: first when they 
entered treatment (when they were asked about the two years prior to entering 
treatment); and then one year and two years later (when they were asked about 
the three months prior to the interview). At each point, they were asked about: 
à use of addiction services (other than the current treatment episode); 
à health care events (i.e. inpatient episodes); and 
à offences committed. 
The cost of addiction services in the two years prior to treatment for the cohort 
was £2.9m. The cost of treatment itself in the next two years was £2.0m. In 
addition, the cohort accessed other treatment services outside this primary 
treatment, which added a further £2.4m over the two years post-treatment. 
Total health costs for the cohort increased from £98,000 in the three months 
before entering treatment, to £137,000 after 1 year and £140,000 after 2 years. 
This increase in health care costs came from increased medical inpatient costs, 
and more A&E and GP visits. The increase in health costs post-treatment is 
explained as treatment may lead to more health conditions being discovered or 
provide an opportunity for existing medical problems to be addressed. 
Crime costs were considerably larger, totalling £5.8m in the three months prior 
to entering treatment. Types of crime included in the study were shoplifting, 
burglary, robbery, fraud, and drug offences. A year after entering treatment, 
crime costs had fallen to £1.8m, but after two years they had increased again to 
£3.0m. 
These costs were then aggregated to compare the total cost in the two years prior 
to treatment with total costs in the two years after treatment. A summary of these 
costs is shown in Table 7. 
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Table 7. NTORS - Summary of costs 
Cost 2 years prior 
to treatment 
2 years following 
treatment 
Net cost / 
benefit 
Main treatment - £2.0m  
Other addiction treatment £2.9m £2.4m  
Total cost of treatment £2.9m £4.4m £1.5m 
Health care costs £0.8m £1.1m -£0.3m 
Crime costs £46.6m £19.3m £27.4m 
Total of health care and 
crime costs 
£47.4m £20.4m £27.0m 
Source: Godfrey at al. (2004) “Economic analysis of costs and consequences of the treatment of drug 
misuse: 2-year outcome data from the National Treatment Outcome Research Study (NTORS)” 
The NTORS study concluded that the ratio of benefits to costs over the two year 
period following treatment was a saving of approximately £18 for every 
additional £1 spent on treatment15. If fraud offences are excluded from the costs 
of crime, then the net benefit of reduced crime falls from £27m to £14m, and 
the saving reduces to £9.50 for every additional £1 spent on treatment. 
The NTORS study gives some idea of the potential cost savings that result from 
adult treatment. However, its applicability to young people is limited in two main 
areas. First, it is a short-term study looking only at the immediate impact of 
treatment in the two years after treatment is received. Second, it considers a 
limited range of treatments targeted predominantly at the use of Class A drugs. 
DTORS 
The NTORS study was recently updated in a new UK study, the Drug Treatment 
Outcomes Research Study (“DTORS”). Like NTORS, DTORS was a national 
longitudinal study looking at the effectiveness of treatment in England. 
The sample contained 1,796 adults seeking treatment for a drug problem, 
recruited from 94 Drug Actions Teams across the country. Participants were 
again restricted to those aged 16 or over when entering treatment. 20% of 
participants were aged 16-24, with the majority of participants aged 25-34. The 
study was not restricted to certain types of treatment, with all patients receiving 
                                                 
15 Godfrey, Stewart and Gossop (2004) “Economic analysis of costs and consequences of the treatment of 
drug misuse: 2-year outcome data from the National Treatment Outcome Research Study (NTORS)” 
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Tier 3 and Tier 4 treatment eligible for the study. The DTORS study differed 
from the previous NTORS work in that it covered all types of drug use including 
cannabis use. However, patients receiving alcohol treatment were not included in 
the study. This again makes the results less applicable to the types of treatment 
typically received by young people. 
Participants were interviewed when entering treatment, and then again 3-5 
months later (first follow-up), and 11-13 months later (second follow-up). At 
each point, they were asked about their drug use, health risk behaviour, 
offending, and mental and physical health; and about the type of treatment they 
had received. Like NTORS, the approach adopted by the DTORS study is to 
take behaviour when entering treatment as a proxy for what would have 
happened in the absence of treatment (i.e. there is no control group). The 
difference between this and the observed behaviour post-treatment is then taken 
as a measure of the impact of treatment. 
Some of the changes in outcomes observed between the initial interview and the 
first and second follow-ups are summarised in Table 8. 
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Table 8. DTORS - Summary of the effects of treatment 
Measure Initial level First follow-up Second follow-up 
Proportion in paid 
employment 
9% 11% 16% 
Proportion in stable 
accommodation 
60% 67% 77% 
Mean weekly income £95 £107 £147 
Proportion who had 
committed an acquisitive 
offence in the last four 
weeks 
40% 21% 16% 
Proportion who had 
committed a high cost 
offence in the last four 
weeks 
8% 3% 4% 
Proportion rating their 
general health as 
‘excellent’ or ‘very good’ 
20% 27% 25% 
Source: Jones et al. (2009) “The Drug Treatment Outcomes Research Study (DTORS: Final outcomes 
report” 
The final element of the DTORS study was an analysis of cost-effectiveness. This 
looked at the costs of treatment and the net benefit of treatment (in terms of the 
savings in economic and social costs) in the 12 months after treatment. This only 
valued short-term benefits and did not consider the long-term benefits of 
effective treatment, such as increased employment and improved productive 
capacity. 
The cost-effectiveness analysis of the DTORS sample showed that structured 
treatment was cost-effective. The estimated cost-benefit ratio was a saving of 
£2.50 in the first year of treatment for every £1 spent on structured treatment. 
The source of this benefit is shown in Table 9. As with the NTORS study, a 
large proportion of the net benefits of treatment come from a reduction in 
offending. 
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Table 9. DTORS – Net costs and benefits 
Costs / benefits Without treatment With treatment Net benefit 
Cost of structured 
treatment 
- £4,914  
Cost of health and 
social care 
£4,543 £3,120 £1,423 
Cost of reported 
offences 
£50,585 £39,967 £10,618 
Total £55,127 £43,087 £12,041 
QALYs 0.63 0.68 0.05 
Source: Davies et al. (2009) “The Drug Treatment Outcomes Research study (DTORS): Cost-effectiveness 
analysis” 
Other evaluations 
In Scotland, the Drug Outcome Research in Scotland study (“DORIS”) sampled 
1,033 drug users entering treatment in 2001. The treatments they received 
included substitute methadone prescribing (27% of participants), non-substitute 
prescribing (28%), counselling (20%), residential rehabilitation (12%), and 
detoxification (12%). The study covered adults with a median age of 27 and a 
range of 16-53. 
Participants were interviewed upon entry, and then again after 8, 16 and 33 
months. After 33 months, 67% of the original cohort was successfully re-
interviewed (694 people). The measure of effectiveness used by DORIS was of 
strict abstinence (i.e. being completely drug free for at least 90 days prior to being 
interviewed). 33 months after treatment, just 8% of drug users reported being 
abstinent. Those who received residential rehabilitation treatments were most 
likely to be abstinent, with 25% of that group drug free, compared to just 5% of 
people recruited from prison-based drug treatment agencies, and 6% of people 
recruited from community-based drug treatment agencies16. This difference was 
despite there being no real difference in the level of dependence for these groups 
when entering treatment. 
After 33 months, 59% of people who were abstinent were in education or 
employment, compared to 29% of those who were not abstinent. 79% of 
                                                 
16 McKeganey et al. (2006) “Abstinence and drug abuse treatment: Results from the Drug Outcome 
Research in Scotland Study” 
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abstinent patients said that their health was much better or somewhat better, 
compared to 47% of not abstinent patients. 13% of abstinent patients had 
committed a crime in the past 17 months, compared to 91% of the non-abstinent 
group. The study showed that whilst there are clear benefits of drug treatment 
for those who become abstinent, the proportion of those receiving treatment that 
become abstinent is small. Using total abstinence as a measure of the 
effectiveness of treatment may not be the best way of capturing treatment 
benefits. 
Also in 2007, PricewaterhouseCoopers produced a report for the Ministry of 
Justice reviewing prison-based drug treatment funding17. This included an 
economic model considering the expected costs and benefits to society of prison-
based drug treatment. The model estimated the potential lifetime cost savings in 
several areas, discounted over a period of 100 years at a rate of 3.5%: 
à excess mortality costs; 
à excess morbidity costs; 
à direct health costs; 
à lost economic output; 
à costs to the criminal justice system; 
à social costs; and 
à intergenerational costs. 
The model calculates the cost savings following immediately effective treatment 
– i.e. it assumes that post-treatment, problem drug users will be able to adopt a 
lifestyle aligned with the aggregate population average in terms of economic, 
health and social activity, adjusted for the characteristics of the population in 
treatment. This immediate and effective transition to the behaviour of a non drug 
user is an extreme scenario, which may overstate the potential benefits of 
effective drug treatment.  
PWC concluded that the discounted lifetime cost saved following immediately 
effective prison-based drug treatment for a 21 year old male was £736,000. Cost 
estimates are largely based on the costs of Class A drug use by Godfrey (2002), 
discussed later in this report. The majority of these cost savings come from 
reductions in the mortality rate, fewer lost earnings, and lower levels of 
acquisitive crime and costs to the criminal justice system. 
                                                 
17 “Report to the Department of Health and Ministry of Justice Review of Prison-Based Drug Treatment 
Funding Final Report” December 2007 (Published March 2008) 
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To summarise, the UK evidence on effectiveness of adult treatment is generally 
positive, but the evaluations tend to be short-term and it is not clear whether it 
can be ‘read across’ to young people’s treatment. 
2.3.2 International evidence 
Evidence relating to young people 
In the US, current research on the effectiveness of young people’s drug treatment 
typically uses longitudinal data from large-scale observational studies, such as the 
Drug Abuse Treatment Outcome Studies (“DATOS”) programme. The DATOS 
programme includes a sample of 3,382 adolescent patients (known as “DATOS-
A”) receiving short term, longer term and residential drug treatment. 
Hser et al. (2001)18 analyse DATOS-A data on 1,167 adolescents aged 11-18 
from four US cities: Pittsburgh; Minneapolis; Chicago; and Portland. They do not 
measure the cost effectiveness of treatment – instead they compare the 
characteristics and behaviour of young people entering treatment with the same 
set of characteristics a year later. They find that there are significant reductions in 
drug use and criminal activity, and improvements in mental health and school 
performance in the year after treatment. The proportion of young people using 
marijuana weekly or more frequently dropped from 80% before treatment to 
44% after treatment. Heavy drinking similarly fell from 34% pre-treatment to 
20% one year later. Reductions in any hard drug use were smaller, falling from 
48% to 42%. They observed improvements in school attendance and reduced 
criminal activity, with the proportion of adolescents committing any illegal act 
falling from 76% to 53% in the year after treatment. 
Morral et al. (2004)19 criticise these sorts of analyses of treatment effectiveness 
because of their inability to distinguish changes in outcomes due to treatment, 
with other changes that would have taken place anyway as the cohort matures. 
They note that this could potentially be addressed by comparing the relative 
effectiveness of two different programmes. Morral et al (2006)20 does this, 
comparing the relative effectiveness of 10 adolescent substance abuse treatment 
programmes in the US. For each of the 10 treatment programmes, they measure 
the effect of the treatment on six outcome measures: recovery; substance 
problems; substance use frequency; illegal activities; emotional problems; and 
days in a controlled environment. They found limited evidence of treatment 
effectiveness, with a positive and significant improvement in outcomes post-
                                                 
18 Hser et al. (2001) “An Evaluation of Drug Treatments for Adolescents in 4 US Cities” 
19 Morral et al. (2004) “Effectiveness of Community-Based Treatment for Substance-Abusing Adolescents: 
12-Month Outcomes of Youths Entering Phoenix Academy or Alternative Probation Dispositions” 
20 Morral et al. (2006) “The Relative Effectiveness of 10 Adolescent Substance Abuse Treatment Programs 
in the United States” 
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treatment in just 11 of the 60 programme and outcome pairs, and negative and 
significant effects in 6 of 60 programme and outcome pairs. 
Dennis et al. (2004)21 examined the clinical and cost-effectiveness of five short-
term outpatient treatments for adolescents with cannabis use disorders and found 
significant and stable post-treatment improvements across all programmes, as 
measured by the number of days of abstinence or the proportion of young 
people in recovery. Specifically, the proportion of adolescents in recovery 
(defined as no drug or alcohol use in the last month) increased from 3% at intake 
to around 24% a year later. The improvement in clinical outcomes post-
treatment did not differ according to which of the five treatment programmes 
was received. The cost per day of abstinence achieved did vary across treatment 
types, with motivational enhancement and cognitive behaviour therapy treatment 
alone being the most cost-effective, and programmes which also included parent 
education sessions, home visits and other services being the least cost effective. 
As with most studies of this type, the authors acknowledge that their results are 
limited by the absence of an appropriate control group with which to compare 
outcomes. 
Other studies of the effectiveness of treatment for adolescents in the US include 
Ruiz (2005)22, who compares treatment outcomes for rural and non-rural 
adolescents. For both groups, there is a steep decrease in substance use three 
months after entering treatment, followed by a gradual increase in the frequency 
of substance misuse over the next 2-3 years. 
The studies mentioned in the previous section tend to focus only on the 
effectiveness of drug treatment, without placing a value on the cost of treatment, 
or the potential value of the benefits of young people’s treatment. Although 
Dennis et al. consider cost-effectiveness to some extent, this does not go so far 
as to place a value on the saving in economic and social costs as a result of 
treatment. 
Evidence relating to adults 
Cost-effectiveness studies of treatment tend to relate to adult drug treatment 
only. Cartwright (2000)23 provides a review of 18 such cost-benefit analyses. The 
review points out the fact that none of the cost benefit studies that were 
reviewed at that time related to adolescent drug treatment, described by 
Cartwright as a “striking area of omission”. Cartwright identifies the short-term 
                                                 
21 Dennis et al. (2004) “The Cannabis Youth Treatment (CYT) Study: Main findings from two randomized 
trials” 
22 Ruiz et al. (2005) “Treatment issues and outcomes for juvenile-justice-involved youth from rural and non-
rural areas” 
23 Cartwright (2000) “Cost-Benefit Analysis of Drug Treatment Services: Review of the Literature” Journal 
of Mental Health Policy and Economics 3, 11-26 
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nature of most of these studies, saying that the long-term nature of addiction is 
not adequately addressed. He also highlights the range of approaches that are 
taken in these studies, both in measuring the costs of treatment, and when 
calculating the potential net benefits of treatment. The review shows that despite 
these problems, even short-run benefits are sufficiently large that the studies 
consistently find a benefit-cost ratio greater than one. 
A subsequent review of 11 studies by McCollister and French (2003) confirmed 
that the net benefit of treatment was almost always positive, with the ratio of 
treatment benefits to treatment costs ranging from 1.33 to 23.33. This review was 
less relevant to young people’s substance misuse as it considered both treatment 
and prevention programmes and looked only at studies of chronic substance 
abusers or problematic users (including problem alcohol users). 
One more recent study by Ettner et al. (2006)24 uses data from the California 
Treatment Outcome Project (“CalTOP”), which interviewed over 2,500 
participants at intake, and then 3 and 9 months later, to measure the cost-
effectiveness of treatment. Questions were asked about use of health services, 
employment, crime, and benefits received. The study found that benefits in the 9 
months post-treatment outweighed the cost of treatment, giving a benefit-cost 
ratio of $7:$1. The majority of the benefit came from reduced crime and from 
higher earnings. Cost-effectiveness varied according to the type of treatment that 
was provided, with higher benefit-cost ratios for out-patient treatment ($11:$1) 
than for residential treatment ($6:$1), and no significant benefits for methadone 
maintenance treatments.  
The cost-effectiveness reviews and studies mentioned above are based on US 
data. Godfrey and Parrott (2000)25 warn that US research may not be applicable 
to the UK. They note that the treatment structures and costs vary considerably 
between the UK and the US. They also point out that the quality of some of the 
US research is again hampered by the absence of a control group. 
To summarise, it appears that there are few, if any, previous studies which 
conducted good CBA evaluation of young people’s treatment. Existing evidence 
tend to be short term. There is some evidence that adult treatments are cost-
effective, but cost-benefit ratios vary by program and country. Overall, it is 
difficult to generalise these studies and to make any inferences about potential 
cost-effectiveness of young people’s treatment in the UK. 
  
                                                 
24 Susan L Ettner, David Huang, Elizabeth Evans, Danielle Rose Ash, Mary Hardy, Mickel Jourabchi, and 
Yih-Ing Hser (2006) “Benefit–Cost in the California Treatment Outcome Project: Does Substance Abuse 
Treatment “Pay for Itself”?”, Health Serv Res. 2006 February; 41(1): 192–213. 
25 Godfrey and Parrott (2000) “How can Policy Makers use Available Evidence on the Cost Benefits of 
Drug Treatment” Journal of Mental Health Policy and Economics 3, 55 
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3 Approach 
This section sets out the approach we haven taken to assess the costs and 
benefits of young people’s drug and alcohol treatment.  
3.1 Conceptual framework 
There are two main elements of our study: 
à Costs: Understanding the amount that is spent in total and per person 
on specialist drug and alcohol treatment for young people in 2008-09. 
à Benefits: Estimating and valuing the benefits of young people’s drug 
and alcohol treatment – measured as a reduction in the economic and 
social costs of drug and alcohol misuse. 
The approach we follow in this analysis captures both the immediate and long-
term benefits of specialist drug treatment for young people, and compares these 
benefits with the cost of providing specialist treatment. In the following sections, 
we set out the approach used by other similar studies in the past, and provide a 
rationale for the approach we have followed. 
3.1.1 Modelling lifetime costs and benefits 
There are two possible ways to assess the costs and benefits of substance misuse 
treatment. 
à comparing in-year costs and benefits of treatment; and 
à comparing lifetime costs and benefits of treatment. 
The in-year approach compares the cost of drug and alcohol treatment provided 
in any one year, with the cost savings realised in that year from current and past 
spending on drug and alcohol treatment. The advantage of looking at in-year 
costs and benefits of treatment is that it provides a measure of the financial 
benefits in any one year from current and previous investment in treatment. This 
is the approach that the NTA have adopted in their ongoing assessment of the 
value for money of adult drug treatment.  
The question being considered by the NTA is what the cumulative effect is of 
the amount spent on drug treatment from 2001-02 to 2008-09. In any one year, 
cost savings up to that point are compared with the amount spent on drug 
treatment in that year and a ratio of benefits to costs is calculated. This includes 
benefits in the current year from money previously spent on drug treatment. For 
example, drug treatment in 2001-02 may turn a person from being a problem 
drug user to a drug user in recovery with a much lower cost to society. The 
savings from this change are counted not just in the year of treatment, but also in 
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subsequent years. This approach can therefore be used to assess the current 
financial impact of a previous policy initiative. 
The Department of Health have similarly developed a model to assess the costs 
and benefits of adult substance misuse treatment, using broadly the same 
information as the NTA. The DH model differs from the NTA model as it 
considers the lifetime costs and benefits of treatment for problematic drug users. 
This is a forward looking approach which compares future outcomes for drug 
users who receive treatment with outcomes for those who do not receive 
treatment. The DH model estimates the lifetime cost of crime, health care, and 
the cost of looked after children, both for young people who receive treatment 
(the intervention scenario) and for young people who do not (the counterfactual). 
The model also includes a measure of the increase in Quality Adjusted Life Years 
(“QALYs”) for adults receiving treatment compared to those who do not receive 
treatment.  
The way we have calculated the benefits of drug and alcohol treatment is more 
closely aligned with the approach adopted by the Department of Health. We 
compare the lifetime cost imposed on society by a sample of young people 
receiving treatment (the intervention scenario) with the lifetime cost to society if 
the same group of young people had not received treatment (the counterfactual). 
The benefit of treatment is the difference between these two figures. If this is 
then bigger than the cost of providing the treatment itself, then there is an overall 
net benefit of providing treatment. 
Some of the benefits of treatment that we capture in our model are immediate 
benefits, but other treatment benefits (i.e. reduced likelihood of becoming an 
adult drug user) have a much longer-lasting impact. These long-term benefits are 
more important for young people (e.g. as they may develop substance 
dependency or become problematic drug or alcohol users if not treated) than for 
adults, where the goal of treatment is primarily to reduce the immediate harm 
done by adult problem drug use than on improving long-term outcomes. A 
forward looking lifetime model which takes into account these potential long-
term benefits is therefore more appropriate for this project. 
3.1.2 Long-term and immediate benefits 
In this study, we have categorised the potential benefits of drug and alcohol 
treatment into two broad groups: 
à immediate benefits; and 
à long-term benefits. 
Immediate benefits 
Substance misuse treatment can have an immediate impact on the behaviour of 
young people. Young people leaving treatment may stop using drugs completely, 
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or significantly reduce their levels of substance misuse. In turn, this may result in 
an immediate change in the harmful behaviour that was previously associated 
with their substance misuse. 
The two principal immediate impacts of drug and alcohol treatment for young 
people that we have included in our model are improved health or reduced 
criminal activity. 
To quantify these benefits, we first need to establish a counterfactual, i.e. the 
economic and social cost to the criminal justice system and to the health care 
system of young people who do not receive treatment. This is done in section 5. 
Section 6 then estimates the potential reduction in crime or health service costs 
that can be attributed to specialist substance misuse treatment. 
Long-term benefits 
Substance misuse treatment for young people may also have longer-term impacts. 
We have included two potential sources of long-term benefits of young people’s 
treatment in our model. 
à reduced likelihood of developing adult substance misuse problems; and 
à improved engagement in education and employment, resulting in 
greater productive capacity and future earnings potential. 
We have drawn upon published sources to assess the probability that young 
people who do not receive treatment will develop substance misuse problems as 
adults. Specifically, we estimate the probability that they will become: 
à problematic drug users (“PDUs”); 
à non-problematic drug users (“non-PDUs”); or 
à problematic alcohol users.26 
We have then used estimates of the lifetime cost to society of each of these three 
types of adult substance misuse to calculate the economic and social cost to 
society in the counterfactual. Further detail on how we have calculated the 
counterfactual cost of adult substance misuse is provided in section 5.2. 
The economic and social costs associated with adult substance misuse are 
potentially very large, particularly for young people who then go on to become 
problem drug users. We recognise that receiving treatment as a young person 
does not remove the possibility that an individual will develop substance misuse 
                                                 
26 A problematic drug user (“PDU”) refers to clients citing opiates, crack cocaine, or both as any of their 
presenting substances. Non-problematic drug users (“non-PDUs”) are clients using illegal drugs other than 
opiates or crack cocaine when presenting for treatment.. Problematic alcohol users include both dependent 
and harmful users (i.e. those drinking over the recommended weekly amount and experiencing health 
problems directly related to alcohol.). 
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problems in later life. However, young people’s substance misuse treatment may 
reduce the probability of developing problems as adults. One long-term benefit of 
treatment is therefore the lower expected cost to society of adult substance 
misuse. We explore the potential effect that treatment has on this cost in section 
6.2. 
Estimates of the cost to society of adult substance misuse typically include crime 
and health costs. They also measure lost output, either through premature death, 
increased absenteeism or lower productivity when at work. However, even for 
young people who do not develop substance misuse problems as adults, there 
may still be long-term education and employment costs relating to their drug use. 
The mechanism for this is as follows. Young people’s substance misuse can 
affect attendance at school, and increase the proportion of young people who are 
not in education, employment or training (“NEET”). This then can have an 
effect on educational attainment and on the qualification levels that are achieved. 
Drug use which leads to lower educational attainment then affects future 
earnings and lowers the productive potential of young people. Substance misuse 
therefore has a further economic and social cost to society, in addition to the lost 
output associated with adult substance misuse.  
3.1.3 Discounting and the career of substance misuse 
The costs of young people’s drug and alcohol treatment tend to be incurred 
immediately27. The benefits on the other hand may persist for a number of years. 
To compare the costs with the benefits, we discount the value of future benefits 
and calculate the net present value of these benefits. This approach has been 
followed consistently throughout the report, and both the immediate and long 
term counterfactual costs and benefits are reported in terms of their net present 
value. 
To discount these future benefits, we then need to establish: 
à the times at which these future benefits will occur; and 
à the rate at which future benefits are discounted. 
Choosing a discount rate is relatively straightforward. Throughout this report we 
have used the recommended Treasury discount rate of 3.5% to discount future 
benefits28. 
Estimating the length of time that the benefits of treatment will persist in the 
future is more difficult. We have assumed that the immediate benefits of drug 
                                                 
27 This approach does not ignore the possibility of incurring further direct costs of treatment for adult 
substance abuse. These expenses are included as a long-term cost associated with adult substance misuse 
and are discounted accordingly in the model. 
28 HM Treasury “The Green Book: Appraisal and Evaluation in Central Government£ 
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and alcohol treatment will last from the point at which young people enter 
specialist treatment, until they turn 18. On average, this is a period of 2 years29. 
After this, the costs of any ongoing substance misuse will be captured by the 
estimates of the cost of adult substance misuse.  
For the subset of young people who develop problems with substance misuse as 
adults, we assume the “career” of adult substance misuse will last for 20 years. 
This is based upon recent detailed work by the NTA on the value for money of 
adult drug treatment30.  
It is possible that the average length of time that an adult uses drugs will differ 
depending on whether they are a PDU, a non-PDU or a problematic alcohol 
user. However, to be consistent with the NTA’s work on adult substance misuse, 
we have assumed a 20-year career of all types of adult substance misuse 
throughout this report. 
3.2 Sample description 
3.2.1 Young people included in the study 
The total number of young people who entered specialist drug and alcohol 
treatment in 2008-09 was 24,053. This is the size of the sample cohort that we 
have modelled.  
Our study looks at the costs and benefits of specialist treatment for all types of 
substance misuse, including treatment for alcohol misuse by young people. 
Previous studies of substance misuse have tended to focus on either drug misuse 
or alcohol misuse, rarely both. 
Table 10 shows that cannabis was listed as the primary drug for 53% of young 
people entering treatment, and that alcohol was listed as the primary drug for a 
further 37% of young people entering specialist treatment. Alcohol misuse is 
therefore an important part of young people’s substance misuse. Focussing only 
on drug misuse would mean that we would capture only a subset of young people 
who benefit from specialist substance misuse treatment. 
                                                 
29 See Table 12. 
30 NTA (2006) “Addiction careers and the natural history of change” 
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Table 10. Number of young people in specialist treatment - by primary drug – 2008-
09 
Primary drug Number of young 
people 
Percentage of young 
people 
Heroin and other opiates 547 2% 
Crack 110 0% 
Cocaine 745 3% 
Amphetamines 230 1% 
Ecstasy 210 1% 
Cannabis 12,642 53% 
Alcohol 8,799 37% 
Solvents 284 1% 
Other 270 1% 
Sub-total 23,836 100% 
Missing or inconsistent data 217  
Total 24,053  
Source: NTA “Substance misuse among young people: The data for 2008-09” 
3.2.2 Drug use 
Young people often require treatment for misuse of multiple drugs. For example, 
young people whose primary drug is crack also tend to be frequent users of 
cannabis and alcohol. NDTMS Treatment Outcomes Profile data records the 
number of days in the past month that a young person has used each type of 
drug. 
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Figure 1. Primary and additional drug use 
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Opiates Crack Cocaine Amphetamines Ecstasy Cannabis Alcohol
Primary drug
Pe
rc
en
ta
ge
 o
f y
ou
ng
 p
eo
pl
e 
en
te
rin
g 
tr
ea
tm
en
t w
ho
 u
se
 
th
es
e 
dr
ug
s
Opiates Crack Cocaine Amphetamines Cannabis Alcohol  
Source: Frontier analysis of TOP data 
Figure 1 shows that young people entering treatment tend to be poly-substance 
users. For example, 40% of mainly opiate users also use crack, alcohol or 
cannabis. Most crack users also use cannabis and alcohol. And there is significant 
overlap in alcohol and cannabis use.  
3.2.3 Age 
Table 11 shows that 75% of young people in treatment are aged 15-17, and 10% 
are less than 14 years old.  
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Table 11. Young people in treatment - by age 
Age Proportion of young people in treatment in 2008-09 
<12 1% 
12-13 2% 
13-14 6% 
14-15 15% 
15-16 23% 
16-17 26% 
17-18 28% 
Source: NTA “Substance misuse among young people: The data for 2008-09” 
The average age of young people in treatment did differ depending on the drug 
they were receiving treatment for. Solvent misusers were the youngest group in 
treatment, followed by those with cannabis and alcohol misuse problems where 
the average age of those in treatment was approximately 16. Heroin and crack 
users in treatment were typically older, with an average age of nearly 17.  
It is worth noting that the TOP data allows us to compare outcomes before and 
after treatment for 16-18 year olds only. We have used this TOP data to estimate 
the level of crime committed in the counterfactual. As 16-18 year olds represent 
54% of the young people in treatment, one concern with using this data is that 
crime committed by this group might not be representative of young people as a 
whole. 
Evidence from the 2006 Offending, Crime and Justice Survey suggests that 
offending by 16-17 year olds is broadly similar to the pattern of offending across 
all 10-17 year olds31. For example, 16% of 16-17 year olds in the survey report 
committing an assault in the last 12 months, compared to 17% of all 10-17 year 
olds. 3% of 16-17 year olds committed vehicle theft, and 12% committed other 
thefts; compared to 2% and 11% of all 10-17 year olds. Based on this evidence, 
looking only at crime committed by 16-17 year olds entering treatment provides a 
reasonable indication of the overall level of crime committed by all young people 
entering treatment. 
                                                 
31 Home Office Statistical Bulletin (2008) “Young people and crime: findings from the 2006 Offending, 
Crime and Justice Survey” 
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Table 12. Average age of young people in treatment - by primary drug 
Primary drug Average age of young people n treatment 
Heroin and other opiates 16.9 
Amphetamines 16.5 
Cocaine 16.6 
Crack 17.0 
Ecstasy 16.2 
Cannabis 15.8 
Solvents 14.8 
Alcohol 16.0 
Other 16.4 
Total 16.0 
Source: Frontier analysis of data from NTA “Substance misuse among young people: The data for 2008-09 
3.2.4 Other demographic characteristics  
We understand form our discussions with stakeholders that young people in drug 
and alcohol treatment face a number of other problems, in addition to their 
substance misuse. Before considering the effect of treatment on substance 
misuse and behaviour relating to substance misuse, we first set out the 
demographic characteristics of young people who receive treatment. This begins 
to identify the range of problems and adverse social circumstances which may 
contribute to substance misuse. It is also helps explain why treatment alone may 
not lead to improvements in behaviour, if other problems exist which are not 
directly tackled by substance misuse treatment. 
In our sample, 62% of young people entering treatment are male. This 
proportion does not vary significantly by age group. 85% of young people treated 
in 2008-09 were white British. 
TOP data (recorded for a subset of young drug users in our sample) shows that 
12% of young people entering treatment in 2008-09 had an acute housing 
problem. A further 5% were said to have a housing risk. Young opiate, crack, 
cocaine and amphetamines users were particularly likely to face housing 
problems. 
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We do not have any further information on the socio-economic characteristics of 
our sample directly, or on other factors such as family breakdown or the nature 
of other problems faced by young drug users in our sample. We know from 
other studies that young people who are serious drug users have multiple 
problems. A report by the Advisory Council on the Misuse of Drugs (2006) 
describes some of the characteristics of young people who are most at risk of 
substance misuse problems32. The report says that drug use by teenagers is more 
common among individuals for whom one or more of the following factors are 
present. 
à Drug use by parents or older siblings 
à Family conflict or poor and inconsistent parenting 
à Truancy and other forms of delinquency 
à Pre-existing behavioural problems 
à Low parental supervision 
à Living with a single or step-parent. 
A survey of 23,000 13-15 year olds in Scotland looked at the relationship between 
family affluence and drug use. It showed that 13-15 year girls in less affluent 
families were more likely to be regular alcohol or regular cannabis users than girls 
in more affluent families. There was no relationship between family affluence and 
alcohol or cannabis use for 13-15 year old boys. 
The Advisory Council on the Misuse of Drugs also references the results of a 
European school student survey on the relationships between young drug and 
alcohol use and a number of other personal characteristics33. Whether teenagers 
live with a single parent or a step-parent was significantly associated with alcohol 
and cannabis use in the UK. The level of parental supervision (measured by 
whether parents knew where their children spent their Saturday nights) was also 
significantly associated with alcohol and cannabis use. Other similar relationships 
were found between older sibling drug use, truancy, and alcohol and cannabis use 
in the UK. 
Although we cannot observe these risk factors directly in our sample of young 
drug users, we can assume that there are a number of other problems faced by 
these young people that may have contributed to their drug use. 
                                                 
32 Advisory Council on the Misuse of Drugs (2006) “Pathways to Problems: Hazardous use of tobacco, 
alcohol and other drugs by young people in the UK and its implications for policy” 
33 Swedish Council for Information on Alcohol and Other Drugs (2004) “The ESPAD Report 2003: alcohol 
and other drug use among students in 35 European countries” 
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4 Cost of young people’s treatment 
This chapter describes the cost of providing specialist treatment for young 
people in 2008-09. First, we set out the different sources of funding in place at 
the time for young people’s drug and alcohol treatment and report the total 
amount of funding available through each stream. Second, we discuss any 
potential local variations in the amount that is spent on young people’s treatment 
or the way the treatment is delivered. 
4.1 Sources of funding 
In 2008-09, there were three principal sources of drug and alcohol treatment 
funding for young people: 
à the Young People’s Pooled Treatment Budget; 
à Local Authority Area Based Grants; and 
à funding from Youth Offending Teams. 
The total funding from each of these three streams in 2008-09 is shown in Table 
13. 
Table 13. Funding for young people's treatment in 2008-09 
Funding stream Amount in 2008-09 
Young Persons Pooled Treatment Budget £24.7m 
Area Based Grant (Home Office) £15.4m 
Area Based Grant (Department for Education) £7.0m 
Youth Justice Board contribution to YOTs £8.5m 
Youth Justice Board spending on treatment via 
secure estate 
£6.5m 
Total £62.2m 
 
Below, we describe each funding steam in more detail. 
4.1.1 Young peoples Pooled Treatment Budget 
The Young People’s Pooled Treatment Budget (“YPPTB”) combines funding 
previously provided by the Department of Health and the Home Office into one 
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single stream of revenue funding. The total amount of funding allocated via the 
Young People’s Pooled Treatment Budget in 2008-09 was £24.7m. 
Funding from the YPPTB is allocated directly to one of 149 local Drug Action 
Teams in England on the basis of local need and key deprivation factors. The 
local DAT then commissions services for young people from NHS or private 
providers. 
Funding for young people’s treatment is ring-fenced for treatment services 
relating specifically to young people. The adult pooled treatment budget, which 
in 2008-09 was £383m, is similarly ring-fenced for treatment. In some cases, 
adults (typically aged 18-19) may also access some of the services commissioned 
for young people as part of transitional arrangements between youth and adult 
services. Where this is the case, some of the adult PTB funding may be allocated 
to young people’s commissioners who are better placed to provide services for 
these individuals. 
4.1.2 Area Based Grants 
The Area Based Grant was a revenue funding stream allocated directly to local 
authorities. This was not ring-fenced for treatment services and local authorities 
were free to use this allocation as they chose.  
In 2008-09, there were two elements of Area Based Grant funding that were 
earmarked for young people’s treatment34. 
à The Home Office contributed £15.4m each year in 2008-09 towards the 
Young People Substance Misuse Partnership. 
à The Department for Education contributed £7.0m in 2008-09 through 
the Area Based Grant for young people’s substance misuse. 
As described below, we have explored with several local commissioners the 
proportion of this Area Based Grant funding that was spent in practice on 
providing specialist treatment for young people. 
4.1.3 Youth Offending Teams 
The Home Office have previously made funding available so that all Youth 
Offending Teams (“YOTs”) in England and Wales have a named drug worker as 
part of their team. The Youth Justice Board reports that there are now 202 
specialist drugs workers and services working with YOTs in England and Wales. 
Drugs workers can be located within the YOT itself, or may be based in drug 
treatment agencies. 
                                                 
34 Memo from Marcus Bell, DCSF, “Confirmation of funding for local areas to reduce young people’s 
substance misuse in England”, 19 March 2008 
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The Home Office contributed £8m in 2008-09 directly to local Youth Offending 
Teams (“YOTs”) via a grant by the Youth Justice Board35. This funding is 
intended to support substance misuse workers within the YOT and to provide 
them with a budget to buy services for treatment.  
4.1.4 Youth Justice Board spending via secure estate 
Finally, in 2008-09 the Youth Justice Board spent £6.5m on treatment via its 
secure estate. The secure estate includes three types of secure accommodation in 
which young people are placed as part of a custodial sentence (secure training 
centres, secure children’s homes, or young offender institutions). 
Substance misuse treatment is then delivered for example in dedicated substance 
misuse facilities in Young Offenders Institutes. These facilities include group and 
one-to-one interview rooms, facilities for voluntary testing, and offices for 
substance misuse staff. 
4.2 Local case studies 
To supplement our understanding of expenditure on specialist substance misuse 
treatment for young people, we have spoken to three local commissioners of 
young people’s substance misuse services. The aim of these local case studies 
was: 
à to understand the proportion of the non ring-fenced funding that was 
spent on specialist treatment; 
à to investigate whether there were any other funding streams that could 
be used to pay for specialist substance misuse services; and 
à to gain a greater understanding of the ways young people come into 
contact with treatment services and how these services are organised at 
a local level. 
These local case studies were selected to cover a range of treatment models. The 
local areas differed in the amount of funding allocated for young people’s 
treatment, the way this money was spent and how the service as a whole was 
structured. 
4.2.1 Funding streams 
The sources of funding for young people’s treatment identified by 
commissioners were broadly similar and matched our understanding of the way 
young people’s treatment services are funded. All received money from the 
YPPTB, from Area Based Grants and from Youth Offending Teams. The 
                                                 
35 http://www.yjb.gov.uk/en-gb/practitioners/Health/SubstanceMisuse/ 
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proportion of funding accounted for by each of these sources is also broadly 
similar, with around 40% of funding coming via the YPPTB, as shown in Table 
14. 
Table 14. Funding split for young people's substance misuse treatment - Local case 
studies 
Funding source Local area 1 Local area 2 Local area 3 
YPPTB 39% 45% 40% 
Area Based Grant (Department for 
Education) 5% 
Area Based Grant (Home Office) 
50% 29% 
23% 
YOTs 10% 12% 8% 
Additional funding from adult 
treatment services  13% 5% 
Additional funding from local 
authorities   11% 
Additional Area Based Grant 
Funding   8% 
Total 100% 100% 100% 
Source: Frontier analysis of proportion of total funding for young people’s treatment provided by each 
funding source – based on interviews with local commissioners 
In one local area, there were no additional sources of funding for young people’s 
treatment other than the major funding streams. Two local commissioners said 
that they received a small amount of funding from adult treatment services. In 
one case, this was for work done in treating some 18-19 year olds more suited to 
the treatment provided by young people’s services36. In the other, this was a 
contribution to support work on parental substance abuse being carried out 
within the Children’s Services division. 
One local area also received an additional allocation from the Area Based Grant 
to support a short-term project to provide two additional substance misuse 
education workers based in schools. The same local area also received additional 
funding from the local authority. 
                                                 
36 The commissioner told us that this was because the adult services tended to be more focused more on 
treating Class A drug use (such as heroin use) and were less appropriate for these individuals. 
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A common theme across the three commissioners we interviewed was that all 
funding provided for young people’s treatment was spent – no funds were 
carried over to the following year. Young people’s treatment services tended to 
be commissioned in large blocks, with one principal provider, and other smaller 
providers contracted to provide specific specialist services37. Most of this 
appeared to be spent on commissioning specialist treatment services, with only a 
small proportion of funding in one local area left over to spend on prevention 
and targeting work. 
In this report, we have taken the total amount of funding allocated for young 
people’s treatment via the YPPTB, the Area Based Grants, and the YOT/YJB 
funding as the total amount that is spent on specialist treatment for young 
people. There may be some other additional funding streams allocated to certain 
local areas which are then spent on drug and alcohol treatment, in which case we 
may understate the total amount that is spent on specialist treatment. 
Alternatively, a proportion of this funding may be spent on providing 
preventative advice and drug information rather than treatment directly. In this 
case, we would overstate the amount spent on specialist treatment. 
On the whole, we believe that the figure of £62.2m is a reasonable estimate of 
the total amount that was spent on specialist treatment services for young people 
in 2008-09. 
4.2.2 Referral routes and service structure 
Young people tend not to self-refer into treatment, with just 11% of young 
people entering treatment nationally in 2008-09 referred by themselves, their 
family or their friends. Self-referrals are more common for adults, but for young 
people the majority of those entering treatment are picked up by other routes. 
The commissioners we spoke to emphasised the need for treatment services to 
work closely with other services better placed to identify those young people with 
a treatment need.  
Approximately 40% of referrals nationally in 2008-09 into young people’s 
substance misuse treatment services came through the criminal justice system. 
When Youth Offending Teams assess young offenders as part of a formal 
criminal justice system response, they conduct a holistic assessment of the 
problems which may have contributed to their offending behaviour. If this 
assessment highlights alcohol or drug misuse they should receive appropriate 
support, including referral into specialist treatment. 
                                                 
37 For example, one provider helped to finance a Tier 3 Child and Adolescent Mental Health Service in 
addition to their primary treatment service. Another mentioned the need to commission expensive Tier 4 
residential treatment for some patients, but that there were currently no young people who received Tier 4 
treatment. 
46  
 
Cost of young people’s treatment  
 
There is also a strong link between education and treatment services, with 19% 
entering treatment in 2008-09 via the education system. One commissioner 
stressed the need to train teachers to increase the number of people who are 
referred into specialist treatment services. One local commissioner provided a 
comparison of those entering treatment via the YOTs, and those entering 
treatment via Education Link. In this one local area, the evidence suggested that 
whilst types of drug use were similar across referral routes, young people entering 
treatment via Education Link tended to be younger than young people entering 
treatment via YOTs. Furthermore, there were fewer unplanned exits and a far 
lower proportion of re-referrals into treatment for those entering through 
Education Link rather than through YOTs. 
The conclusion that can be drawn in this particular local area is that young 
people entering treatment through the criminal justice system tend to be older 
drug users, who are more likely to drop out or return for further treatment. 
However, it is not clear how this description of referral routes compares to the 
national picture and we should be cautious when interpreting this result. 
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5 The counterfactual 
Drug and alcohol misuse imposes economic and social costs both on substance 
users, their families and on society as a whole. These costs include the costs of 
crime, poor health, premature deaths, poor educational and employment 
outcomes and so on. Specialist treatment is expected to reduce young people’s 
substance misuse and therefore to avert some of these costs. Our objective is to 
estimate this reduction in the economic and social costs due to the YP specialist 
treatment. However, before we can do that we need to understand what would 
have happened in the absence of treatment, i.e. to assess the total costs that the 
young people who are currently in treatment would have imposed on society if 
not treated. These costs are called the counterfactual costs and are highlighted in 
Figure 2. 
Figure 2. The counterfactual cost of young people's drug and alcohol misuse 
Cost of adverse health 
outcomes
With 
treatment
Cost of criminal 
activity
Cost of long-term 
substance misuse
Without 
treatment
With 
treatment
Without 
treatment
With 
treatment
Without 
treatment
Immediate costs Long-term costs
Counterfactual costs
 
 
To establish an appropriate counterfactual for young people in the absence of 
treatment, we have drawn upon a combination of previously published literature 
and reports, survey evidence, and evidence from the NDTMS/TOP data. 
We split the counterfactual costs into (i) immediate costs and (ii) long-term costs, 
as illustrated by Figure 3 below.  
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Figure 3. Counterfactual costs: immediate and long term 
Young substance 
misusers
Immediate costs:
- Crime
- Poor health
- Premature 
deaths from overdose
Become adult 
substance misusers
(develop dependency)
Do not use drugs/ 
alcohol as adults
Long term costs:
- Crime
- Poor health
- Low productivity
- Poor employability    
Potential long term 
costs:
- poor educational 
qualifications (as a result 
of using drugs and being 
NEET as young people)
 
Source: Frontier Economics 
Immediate costs include: 
• the costs of crime committed by young substance misusers in any given year; 
and  
• the NHS costs associated with treatment of drug and alcohol-related 
conditions affecting young people (such as alcohol poisoning and drug 
overdose). 
Long-term costs are incurred if young substance misusers become problematic 
drug users (PDUs) or problematic alcohol users as adults. If this happens, the 
costs imposed on society are likely to increase further as adult PDUs and 
problematic alcohol users tend to commit more frequent and serious crimes, 
impose higher costs on the NHS, have high unemployment rates and poor 
educational attainment. 
There exist several studies estimating the long-term costs associated with adult 
substance misuse. However, one needs to be careful when applying these 
estimates in the context of young people’s CBA as not all young people who 
abuse drugs as teenagers would necessarily become adult PDUs or problematic 
alcohol users.  
In order to understand what proportion of young people are likely to develop 
adult substance misuse problems, we look at the literature exploring patterns of 
drug and alcohol misuse over time. This is discussed in detail in Section 5.2.3. 
The general conclusion seems to be that between 30% and 40% of 
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moderate/heavy teenage alcohol and cannabis users would develop adult 
substance misuse problems while the remaining 60%-70% would experience 
natural remission (even if not treated). The proportion is however higher for 
teenage Class A drug users (up to 95% of teenage Class A drug users continue to 
use drugs in adulthood). 
We combine these proportions (probabilities) with the unit costs of adult 
substance misuse to estimate the expected long-term counterfactual costs that are 
likely to be incurred in the absence of treatment.  
Finally, those young people who do not become PDUs or problematic alcohol 
users as adults might still incur long term costs. Indeed, young substance 
misusers are more likely to be NEET (not in education, employment or training) 
and leave school without qualifications (discussed in detail below). This may 
affect their whole working life, resulting in lower wages and poorer employment 
prospects. 
Below we explain how we calculate immediate counterfactual costs and the long 
term counterfactual costs in more detail. 
5.1 Immediate costs 
We identify two types of immediate counterfactual costs associated with young 
people’s substance misuse. These are the cost of crime committed by young 
substance misusers and the NHS costs associated with treatment of drug and 
alcohol-related conditions affecting young people (such as alcohol poisoning and 
drug overdose). Clearly, there are various other problems associated with drug-
taking, e.g. truancy and broken families. These problems also impose economic 
and social costs on young people, their families and society. However, some of 
these costs are difficult to quantify (e.g. strained family relationships), while 
others are better classified as long-term costs (e.g. truancy, which is likely to lead 
to poor educational outcomes and low employability, which means lost output 
and earnings over individuals’ working life). These latter costs are likely to be 
significant and are taken into account in our estimates of the long-term 
counterfactual costs. 
It is likely that young people’s substance misuse contributes to further costs, 
including those associated with children’s services, and particularly the costs of 
being taken into care. However, it was not possible to isolate the proportion of 
these costs attributable to substance misuse and so these were not factored into 
the overall cost figures. Throughout the report we have taken a cautious 
approach to constructing cost and benefit figures to ensure that the final 
calculations provide a robust lower estimate of any projected savings. 
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5.1.1 Crime 
To estimate the cost to the criminal justice system in the counterfactual, we have 
used data from the NDTMS Treatment Outcomes Profile. TOP data records the 
number of crimes committed by young people when they enter and when they 
leave treatment. In this report, we have used the amount of crime committed by 
young people entering treatment as a proxy for the level of criminal activity by 
young people in the absence of treatment (i.e. the counterfactual). 
There are two points to note in relation to the TOP crime data. First, offending 
behaviour in the TOP is self-reported. As a result, we may underestimate both 
the frequency and the prevalence of offending by young people. Our estimates of 
the cost of crime presented below can therefore be thought of as a conservative 
estimate. Second, the TOP data only covers 16 and 17 year olds in treatment. 
However, as outlined in section 3.2.3, the pattern of offending amongst 16-17 
year olds is broadly similar to the pattern of offending across all 10-17 year olds. 
Offending in the TOP data can therefore be considered broadly representative of 
offending by all young people receiving specialist treatment. 
A summary of the immediate counterfactual cost to the criminal justice system of 
crime committed by young people in the absence of treatment is given in Table 
15. 
Table 15. Immediate costs of crime in the counterfactual 
Type of crime Year 1 Year 2 (discounted) Total 
Shoplifting £18.4m £17.8m £36.1m 
Assault £57.6m £55.7m £113.3m 
Theft £22.2m £21.4m £43.6m 
Total £98.2m £94.9m £193.0m 
Source: Frontier analysis 
The following sections explain how the immediate cost of crime in the 
counterfactual has been calculated. 
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Number of crimes committed by young people in the counterfactual 
Certain types of crime are more closely linked to substance misuse than others38. 
The TOP data we have received records information on three types of drug-
related crime committed by young people39. 
à The number of days in the past 28 days that they had committed a 
shoplifting offence. 
à Whether or not they had committed an assault in the past 28 days. 
à Whether or not they had committed a theft in the past 28 days. 
Using this, we can estimate the annual number of crimes committed per person 
in the counterfactual for each of these three types of crime.40 Since young people 
on average enter treatment aged 1641, we have modelled the number of crimes 
they would have committed in the absence of treatment over a period of two 
years until they turn 18. After this point, any crimes they commit will be captured 
in our estimates of the cost of adult drug misuse.  
Shoplifting 
Responses to the question on the frequency of shoplifting and drug selling are 
recorded as either: 0 days; 1-9 days; or 10+ days; or not answered. Around 7% of 
young people did not answer the question on their shoplifting behaviour. 1.5% 
of young people said that they had shoplifted on 10 or more days in the last 
month. A further 4.3% admitted shoplifting on 1-9 days. The level of shoplifting 
did vary according to the primary drug that young people were receiving 
treatment for, as shown in Figure 4. 
                                                 
38 For example, see UK Drug Policy Commission (2007) “An Analysis of UK Drug Policy: A Monograph 
Prepared for the UK Drug Policy Commission” 
39 TOP data also records information on the amount of drug selling carried out by young people in the past 
28 days. The Home Office however describes selling drugs as a “victimless crime”, and does not measure 
the economic and social costs associated with it. We have therefore not assigned a cost to drug selling, and 
have not included drug selling crimes in our analysis. 
40 The questions in the TOP data ask about criminal behaviour in the past 28 days. To convert this to an 
annual figure, we have multiplied the total crime committed by 12 months. This assumes that the extent of 
offending reported by young people immediately prior to entering treatment would remain constant 
throughout the year, in the absence of specialist treatment.. 
41 See Table 12. 
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Figure 4. Shoplifting by young people entering treatment - by primary drug 
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Source: TOP data on 16-17 year olds entering treatment in 2008-09 
Note: The percentages reported above exclude those who did not answer the question on their shoplifting 
behaviour 
Young opiate users were far more likely to shoplift than users of other drugs, and 
did so more frequently, with 14% shoplifting on 10 or more days in the last 
month. On the other hand, only 1% of alcohol and cannabis users shoplifted 
more than 10 times in the month before they entered treatment. 
To calculate the number of shoplifting offences in the counterfactual, we first 
calculate the weighted average number of shoplifting days in the past 28 days. 
Then, combining this with the total number of young people in treatment in 
2008-09, we can calculate the expected total number of shoplifting offences that 
would have been committed by our sample over the next two years in the 
absence of treatment. This is shown in Table 16. 
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Table 16. Shoplifting by young people entering treatment 
Primary drug Average number 
of shoplifting 
offences per 
person per month 
Number of 
people 
treated in 
2008-09* 
Number of 
shoplifting 
offences per 
month 
Number of 
shoplifting 
offences per 
year 
Opiates 3.21 552 1,770 21,242 
Crack 1.16 111 129 1,545 
Cocaine 0.73 752 548 6,581 
Amphetamines 0.94 231 216 2,595 
Ecstasy 0.93 212 197 2,361 
Cannabis 0.42 12,757 5,377 64,522 
Alcohol 0.43 8,879 3,844 46,126 
Total 0.51 23,494 12,081 144,973 
Source: Frontier analysis of NTA data 
Note: * The figures for the number of people treated given here do not match the figures given in Table 10. 
This is because we have scaled up the number of young people treated proportionally to include young 
people in treatment where a primary drug was not recorded. 
Assault 
7% of those asked whether they had committed an assault in the past 28 days 
refused to answer. 12% said that they had committed an assault, and the 
remaining 81% said that they had not done so in the past month. The level of 
crime again varied depending on the primary drug, with a larger proportion of 
alcohol users reporting that they had committed an assault than cannabis or 
opiates users, as shown in Figure 5. 
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Figure 5. Assault by young people entering treatment - by primary drug 
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Source: TOP data on 16-17 year olds entering treatment in 2008-09 
Note: The percentages reported above exclude those who did not answer the question on assaults 
The data on theft and assault only reports whether or not a young person has 
committed the crime in the past month – it does not set out whether this has 
happened more than once. To be conservative, we have assumed that if a young 
person committed an assault in the past month, they did so only once. Our 
estimates of the number of assaults and theft may therefore understate the true 
amount of crime committed by these young people. 
The estimated number of assaults committed by young people in the 
counterfactual over a period of two years is shown in Table 17 
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Table 17. Assault by young people entering treatment 
Primary drug Percentage who 
committed 
assault in the 
past 28 days 
Number of 
people 
treated in 
2008-09* 
Number of 
assaults per 
month 
Number of 
assaults per 
year 
Opiates 5% 552 29 351 
Crack 12% 111 13 160 
Cocaine 15% 752 112 1,343 
Amphetamines 15% 231 34 411 
Ecstasy 17% 212 35 424 
Cannabis 10% 12,757 1,333 15,996 
Alcohol 15% 8,879 1,331 15,977 
Total 12% 23,494 2,888 34,662 
Source: Frontier analysis of NTA data 
Note: * The figures for the number of people treated given here do not match the figures given in Table 10. 
This is because we have scaled up the number of young people treated proportionally to include young 
people in treatment where a primary drug was not recorded. 
Theft 
8% of those asked said that they had committed a theft in the past 28 days. 85% 
said that they had not, and 6% refused to answer. Young people treated primarily 
for opiate or crack use typically committed more theft than young people treated 
for cannabis, alcohol, or ecstasy misuse, as shown in Figure 6. 
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Figure 6. Assault by young people entering treatment - by primary drug 
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Source: TOP data on 16-17 year olds entering treatment in 2008-09 
Note: The percentages reported above exclude those who did not answer the question on theft 
The estimated number of thefts committed in the counterfactual is shown in 
Table 17. 
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Table 18. Theft by young people entering treatment 
Primary drug Percentage who 
committed theft in 
the past 28 days 
Number of 
people treated 
in 2008-09* 
Number of 
thefts per 
month 
Number of 
thefts per year 
Opiates 17% 552 95 1,141 
Crack 16% 111 18 213 
Cocaine 11% 752 86 1,033 
Amphetamines 11% 231 26 308 
Ecstasy 4% 212 9 106 
Cannabis 9% 12,757 1,101 13,212 
Alcohol 6% 8,879 561 6,730 
Total 8% 23,494 1,895 22,743 
Source: Frontier analysis of NTA data 
Note: * The figures for the number of people treated given here do not match the figures given in Table 10. 
This is because we have scaled up the number of young people treated proportionally to include young 
people in treatment where a primary drug was not recorded. 
Unit costs of crime 
Estimates of the economic and social cost of different types of crime are set out 
in two reports by the Home Office. These cost estimates all include three 
elements: 
à costs in anticipation of crime (defensive expenditure, insurance 
administration); 
à costs as a consequence of crime (including the physical and emotional 
impact on victims, value of property stolen/damaged, lost output and 
health services); and 
à costs in response to crime (criminal justice system costs). 
These estimates are widely referenced in other cost benefit studies. The estimates 
are therefore a good and broadly accepted measure of both the economic and 
social cost to society as a result of these crimes. 
We have used these estimates (uprated to reflect current prices) in our analysis to 
place a value on the cost to society of drug-related crimes committed by young 
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people in the counterfactual. The specific unit cost estimates that we have used in 
this report are shown in Table 19. 
Table 19. Unit costs of crime 
Type of crime In 1999 prices In 2003 prices In 2009 prices 
Theft £600 £844 £974 
Common assault £540 £1,440 £1,663 
Theft from a shop £100 - £127 
Source: Home Office: The economic and social costs of crime against individuals and households 2003/04; 
The economic and social costs of crime, 2000 
Note: Figures in bold reflect the unit cost of crime used in our analysis, updated to reflect 2009 prices using 
the GDP deflator. Other figures in the table set out the raw data in the Home Office reports used to 
calculate these unit costs. Where the unit cost of crime is estimated in both the 2000 and 2003/04 reports, 
unit costs in 2009 are based on the more recent estimate, and the previous estimate is shown in grey. 
Total cost of crime 
Table 20 combines the counterfactual number of crimes and the unit cost of 
these crimes to show the counterfactual cost per year. We estimate the total cost 
of crime to be £193.0 million over a two year period - £98.2m in the first year 
and £94.9m in the second year (discounted). 
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Table 20. Immediate annual cost of crime in the counterfactual – by primary drug and type of 
crime 
Primary 
drug 
Number of 
shoplifting 
offences 
Cost of 
shoplifting 
offences 
Number 
of 
assaults 
Cost of 
assaults 
Number 
of thefts 
Cost 
of 
thefts 
Total 
cost of 
offences 
Opiates 21,242 £2.7m 351 £0.6m 1,141 £1.1m £4.4m 
Crack 1,545 £0.2m 160 £0.3m 213 £0.2m £0.7m 
Cocaine 6,581 £0.8m 1,343 £2.2m 1,033 £1.0m £4.1m 
Amphetami
nes 2,595 £0.3m 411 £0.7m 308 £0.3m 
£1.3m 
Ecstasy 2,361 £0.3m 424 £0.7m 106 £0.1m £1.1m 
Cannabis 64,522 £8.2m 15,996 £26.6m 13,212 £12.9m 
£47.7m 
Alcohol 46,126 £5.8m 15,977 £26.6m 6,730 £6.6m £39.0m 
Total 144,973 £18.4m 34,662 £57.6m 22,743 £22.2m 
£98.2m 
Source: Frontier analysis 
The estimates of the number of offences in the previous sections are based on 
the amount of crime committed by young people entering treatment aged 16 and 
17. Our approach takes this as a proxy for the level of crime committed by all 
young people when they enter treatment. 
We cannot assess directly using the NDTMS/TOP data how the level of crime 
committed by young people entering treatment varies by age. However, evidence 
from the Offending Crime and Justice Survey suggests that the amount of crime 
committed by young people peaks at age 14-15, after which it declines42. The 
survey also shows that crime committed by 16-17 year olds (the typical age that a 
young person would enter treatment) is broadly representative of crime 
committed by all young people. We therefore believe that these estimates provide 
a reasonable picture of the level of crime committed by young people entering 
treatment for misuse of drugs or alcohol.  
                                                 
42 Home Office Statistical Bulletin (2008) “Young people and crime: findings from the 2006 Offending, 
Crime and Justice Survey” 
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5.1.2 Health 
Our estimate of the counterfactual health care costs of young people’s drug and 
alcohol misuse fall into two broad categories: 
à the hospital costs of young people’s drug and alcohol misuse; and 
à the cost of drug related deaths by young drug and alcohol users. 
A summary of the immediate total cost to the health care in the absence of 
treatment is given in Table 21. 
Table 21. Immediate health care costs 
Type of health care cost Year 1 Year 2 Total 
Hospital costs £0.1m £0.1m £0.2m 
Drug and alcohol related deaths £4.2m £4.1m £8.2m 
Total £4.3m £4.2m £8.4m 
Source: Frontier analysis 
A large proportion of the immediate health care costs associated with young 
people’s drug and alcohol misuse come from the cost of drug and alcohol related 
deaths, rather than from hospital costs. Below, we describe in more detail how 
these estimates have been calculated. 
Hospital costs 
To estimate the immediate cost of hospital care for young drug and alcohol users 
in the counterfactual, we have drawn upon data from the NHS Information 
Centre for Health and Social Care (“IC”) and from the DH reference cost 
database. The IC produces information on the number of drug and alcohol 
related hospital episodes for young people, and the reference cost database allows 
us to estimate the associated costs. 
Number of drug and alcohol related inpatient episodes 
The IC records two types of drug related episodes 
à episodes where the primary or secondary diagnosis was of drug related 
mental health and behavioural disorders; and 
à episodes where there was a primary diagnosis of poisoning by drugs. 
The number of these episodes for young people in 2008-09 is shown below. 
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Table 22. Number of drug related inpatient episodes for young people in 2008-09 
Episode type Number of 
episodes 
by people 
aged 0-16 
Number of 
episodes 
by people 
aged 16-24 
Estimated number of 
episodes by young 
people aged 0-17 
Drug related mental health and 
behavioural disorders (primary 
or secondary diagnosis) 
318 6,721 1,812 
Poisoning by drugs (primary 
diagnosis) 
711 2,741 1,320 
Source: NHS Information Centre for Health and Social Care 
Notes: The estimated number of episodes for young people aged 0-17 is calculated by adding all of the 
episodes for those aged 0-16 to two ninths of the number of episodes for those aged 16-24.  
The total number of drug related inpatient episodes shown above covers all drug 
and alcohol misusers, not just those who receive treatment. We must therefore 
estimate the proportion of these hospital admissions accounted for by young 
people in our sample. 
One proxy for this is the proportion of young people with serious drug or 
alcohol use that are engaged in effective treatment over the course of a year. A 
potential drawback with this approach is that our sample may be made up of 
particularly problematic drug and alcohol users who account for more episodes 
per person than an average drug and alcohol user. If this were true, we would 
understate the proportion of admissions that are accounted for by our sample. 
We have therefore only included the most frequent drug and alcohol users in our 
measure of the total population, so our sample should be broadly representative 
of these users. 
To estimate the proportion of serious young drug users, we have again used 
information from the NHS IC. We estimate that the number of young people 
using illicit drugs regularly is approximately 320,000. Regular use for 11-15 year 
olds is defined as taking drugs at least once a month in the past year. Regular use 
for 16-17 year olds is defined as taking drugs in the past month. Just 15,000 
young people were treated for drug use in 2008-09. Our sample therefore 
represents approximately 4.7% of all young people regularly using illegal drugs.  
Taking this estimate of the proportion of drug related hospital episodes 
accounted for by our sample, we calculate that there are 85 mental health and 
behavioural episodes for our sample per year, and 62 drug poisoning episodes for 
our sample each year. 
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As we have done when estimating the counterfactual cost of crime, we have 
assumed that any immediate benefits (such as lower healthcare or crime costs) 
will last only from the point at which a young person enters treatment (typically 
age 16), to the point when they turn 18. After this point, any further health care 
costs will be captured by our estimates of the cost of adult drug use. 
Taking this into account, over a two year period our sample will therefore 
experience: 
à 171 drug related mental health and behavioural disorder episodes; and 
à 124 drug poisoning episodes. 
The IC similarly report alcohol related inpatient episodes by age, although this 
data is only available for 2007-08. Alcohol related inpatient episodes are grouped 
according to whether they can be wholly or partly attributed to alcohol misuse. 
We have taken the conservative approach of only including hospital episodes that 
can be wholly attributed to alcohol misuse in our study.  
Table 23. Number of alcohol related inpatient episodes for young people in 2007-08 
Episode type Number of 
episodes 
by people 
aged 0-16 
Number of 
episodes 
by people 
aged 16-24 
Estimated number of 
episodes by young 
people aged 0-17 
Alcohol related NHS hospital 
admissions (wholly attributable 
to alcohol) 
4,700 20,600 9,278 
Source: NHS Information Centre for Health and Social Care 
Notes: The estimated number of episodes for young people aged 0-17 is calculated by adding all of the 
episodes for those aged 0-16 to two ninths of the number of episodes for those aged 16-24.  
We have carried out a similar exercise to estimate the proportion of alcohol 
related hospital admissions accounted for by our sample. Again, we first estimate 
the number of moderate or heavy alcohol users. For young people aged 11-15, 
we have interpreted this as the number of 11-15 year olds that drank 14 or more 
units of alcohol in the past week. For those aged 16-17, we have taken the 
number of 16-17 year olds defined as hazardous or harmful alcohol users (i.e. 
those with an Alcohol Use Disorders Identification Test “AUDIT” score of 
more than 8). Using this approach, we estimate that there are around 660,000 
young people drinking alcohol in sufficient quantities such that it may result in 
health problems. The number of young people in our sample treated for alcohol 
misuse is just 8,799. Our sample therefore represents approximately 1.3% of 
harmful young alcohol users. 
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Using this estimate, we calculate that our sample accounts for 123 alcohol related 
NHS hospital admissions that are wholly attributable to alcohol per year, and 246 
over a two year period. 
Cost per inpatient episode 
The NHS reference cost database in 2008-0943 presents the national average unit 
cost for different types of inpatient and outpatient episodes. Young people who 
misuse drugs and alcohol will typically be admitted for short stay non-elective 
inpatient procedures. Our cost estimates have therefore been drawn from the 
“Non-elective Inpatient (Short Stay)” schedule of reference costs. 
The drug and alcohol related inpatient episodes described in the previous section 
are defined according to their disease classifications44. However, reference costs 
contain cost information on the procedures that are carried out. We have 
therefore tried to match the procedure to the diagnosis to estimate the cost of a 
typical inpatient episode, as shown in Table 24. 
                                                 
43 
http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_
111591  
44 More specifically, inpatient episodes are classified according to the International Classification of Diseases 
(ICD-10) codes. 
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Table 24. Unit cost of drug related inpatient episodes for young people 
Type of episode Matched procedure Average cost per 
episode  
(# of episodes in 
brackets) 
Drug related mental 
health and behavioural 
disorders (primary or 
secondary diagnosis) 
Behavioural Disorders with 
length of stay 1 day or less 
£431 
Poisoning, toxic, 
environmental and unspecified 
effects with major CC 
£389 (2,193) 
Poisoning, toxic, 
environmental and unspecified 
effects with intermediate CC 
£338 (38,637) 
Poisoning, toxic, 
environmental and unspecified 
effects without CC 
£329 (44,626) 
Poisoning by drugs 
(primary diagnosis) 
Weighted average cost of 
poisoning 
£334 
Source: NHS Reference Cost Database 2008-09 
Notes: CC in the above definitions stands for “complications and co-morbidities” 
Wholly attributable alcohol inpatient episodes cover a range of diagnoses. Across 
all patients, mental and behavioural disorders due to alcohol account for 65% of 
NHS hospital admissions. Alcoholic liver disease accounts for 17% of 
admissions, and the toxic effect of alcohol accounts for 14%. The remaining 4% 
are for other wholly attributable conditions.  
For young people, we assume that they will not be admitted to hospital for liver 
disease, or for other long-term wholly attributable conditions as they have not 
typically had the time to become dependent on alcohol. Alcohol related 
admissions for young people we therefore assume are split between mental and 
behavioural disorder episodes and toxic effects (i.e. poisoning episodes). 
Applying the same unit cost estimates as above, we can calculate a weighted 
average cost per wholly attributable hospital episode for young people. 
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Table 25. Unit cost of alcohol related inpatient episodes for young people 
Type of episode Estimated proportion of 
episodes for young people 
Average cost per 
episode 
Mental and behavioural 
disorders due to use of alcohol 
83% £431 
Toxic effect of alcohol 17% £334 
Weighted average cost per 
episode 
 £415 
Source: NHS Reference Cost Database 2008-09 and NHS Information Centre for Health and Social Care 
Total cost of drug and alcohol related hospital episodes 
Combining our estimates of the number of drug and alcohol related hospital 
admissions in the counterfactual with the unit cost of these episodes, we can 
estimate the immediate annual counterfactual cost of hospital care. This is 
summarised in Table 26. 
Table 26. Immediate annual cost of drug and alcohol related hospital admissions in 
the counterfactual 
Type of episode Number of episodes Total cost 
Drug related mental health and behavioural 
disorders (primary or secondary diagnosis) 85 £36,768 
Poisoning by drugs (primary diagnosis) 62 £20,780 
Alcohol-related NHS hospital admissions 
(wholly attributable to alcohol) 123 £50,976 
Total  £108,524 
Source: Frontier analysis 
It is worth noting that these estimates are likely represent a lower bound of the 
true counterfactual costs as we only include hospital episodes which are wholly 
attributable to alcohol and drug misuse and because we do not include costs of 
GP visits (due to a lack of data). 
Drug and alcohol related deaths 
The Office for National Statistics reported that there were 51 deaths related to 
drug misuse by those aged less than 20 in 2008. This included deaths from 
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mental or behavioural disorders due to drug use, accidental and intentional 
poisoning. There were 4 deaths related to alcohol misuse by those aged under 20 
in 2008. 
There are a number of important caveats surrounding these estimates on the 
number of drug and alcohol related deaths by young people. First, this covers 
deaths by young adults 18 and 19, not just by young people aged less than 18. We 
may therefore overstate the number of drug and alcohol related deaths for young 
people. However, it is also reasonable to assume that drug misuse by young 
people aged less than 18 may have contributed significantly to the death of 18-19 
year olds. 
Second, it is possible that whilst the use of drugs or alcohol was not directly 
responsible for the death of an individual, it may have been an important 
contributory factor. We have taken the conservative approach of not including 
deaths which could be partly attributed to drug or alcohol misuse in this study. 
The estimate of the value of a human life saved used in the Department for 
Transport’s project appraisals in 2007 was £1.64m. In 2009 prices, this becomes 
£1.71m. This is the value we have assigned to a life saved in our model. The 
elements of the value of a life are shown below. 
Table 27. Cost of a life saved 
 Lost output Human costs Medical and 
ambulance 
Total 
In 2007 prices £556,660 £1,080,760 £970 £1,638,390 
In 2009 prices £581,022 £1,128,060 £1,012 £1,710,094 
Source: Department for Transport WebTAG guidance documents; Uprated using the GDP deflator 
Based on the number of lives lost due to drugs and alcohol in the counterfactual, 
and the value of a life saved, we can calculate the immediate counterfactual cost 
of drug and alcohol related deaths for young people. We have again assumed, as 
we did for hospital health care costs, our sample accounts for just 4.7% of drug-
related deaths, and 1.3% of alcohol related deaths by young people. We have also 
assumed that the number of drug and alcohol deaths is constant per year over the 
two years. Taken together, the number of drug related deaths we have modelled 
in the counterfactual is 4.8 (2.4 per year) and the number of alcohol related 
deaths over the two year period is 0.1 (0.05 per year). 
The annual cost of drug related deaths is summarised in Table 28 
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Table 28. Immediate annual cost of drug and alcohol related deaths 
Drug and alcohol related 
deaths 
Number of deaths in the 
counterfactual 
Economic and social cost 
of deaths 
Drug related deaths 2.40 £4.1m 
Alcohol related deaths 0.05 £0.1m 
Total 2.45 £4.2m 
Source: Frontier analysis 
5.2 Long term costs 
5.2.1 Costs associated with poor educational qualifications 
Young substance misusers are more likely to be NEET (not in education, 
employment or training) than young people on average. DfE statistics show that 
only 9% of 16-18 year olds were NEET in 200945. On the other hand, the 
NDTMS data shows that 45% of the young people in treatment were NEET, 
suggesting that the problem is more widespread among substance misusers.  
The proportion of young people that are NEET varies according to the primary 
substance for which treatment is being provided. The proportion of young drug 
users in treatment for opiate and crack use that are NEET is 62% and 55% 
respectively. The proportion of young drug users in treatment for cannabis and 
alcohol use that are NEET is similar to the average of 45% across all young 
people entering treatment in 2008-09. 
Being NEET between 16 and 18 years of age leads to poorer educational 
outcomes and poorer employment prospects later in life. A study by the 
University of York46 assesses the long-term costs of being NEET. It estimates 
that the cost of educational underachievement and poor employment prospects is 
between £92,000 and £356,000 per person (in NPV terms). 
Adjusting for the probability of being NEET among young substance misusers, 
we find that average incremental long-term counterfactual cost per young person 
in treatment is between £33,100 and £128,300, with the central estimate of 
£80,700 (the average between the low and the high estimate). This suggests that 
                                                 
45 http://www.education.gov.uk/16to19/participation/neet/a0064101/strategies-for-16-to-18-year-olds-
not-in-education-employment-or-training-neet 
46 “Estimating the life-time cost of NEET; 16-18 year olds not in Education, Employment or Training”, 
research undertaken for the Audit Commission, University of York, 2010 
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those young substance misusers who do not develop long-term substance misuse 
problems may still incur significant long-term costs throughout their working life. 
This is due to their poorer educational qualifications and poorer resulting 
employment prospects. 
5.2.2 Costs associated with developing substance misuse problems 
In addition to poor educational outcomes and lower employability, young 
substance misusers also run the risk of developing substance misuse problems 
and suffering its long-term consequences as adults. To estimate whether young 
people who do not receive treatment will develop adult substance misuse 
problems, we have gone through three steps: 
1. Use academic studies and published reports to determine the likelihood 
that moderate or heavy use as a young person will result in adult 
substance misuse problems. 
2. Use academic studies and published reports to establish the economic and 
social costs associated with adult substance misuse. More specifically, we 
look at three types of outcomes – problematic drug use (PDU), non-
problematic drug use (non-PDU) and problematic alcohol use – and 
assess the costs of crime, poor health, premature deaths and low 
productivity/lost output associated with each of these outcomes. 
3. Estimate the number of young people who received treatment in 2008-09 
who would have become adult PDUs, non-PDUs or problematic alcohol 
users in the absence of treatment and the costs associated with these 
future outcomes. 
5.2.3 Evidence on long term consequences of young people’s substance 
abuse 
Cannabis and alcohol 
There is evidence showing that alcohol and drug misuse by teenagers may lead to 
adult problematic substance misuse, with frequency of use and age of initiation 
being among the main factors. 
In a longitudinal study conducted by Filmore (1975), 206 respondents were 
followed up from a large previous study of drinking patterns of 17,000 American 
college students. The study found that 40% of those, who were identified as 
problem alcohol users during the college years, also met this criterion in middle 
age. Filmore concluded that in terms of alcohol misuse, young people 
experienced an erratic pattern of non-chronic problems with a 50-60 per cent 
chance of natural remission in men and 70 per cent in women. 
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Bonomo et al. (2004)47 focus on alcohol dependency only and find that frequent 
drinking and binge drinking are associated with alcohol dependence in young 
adulthood. Frequent use increased odds for later dependence at least six fold. 
The relationship between the frequency of use in adolescence and dependence in 
adulthood remains significant even if other factors are taken into account. The 
authors conclude: “our study demonstrates that the clearest predictor of alcohol dependence in 
young adults was regular recreational alcohol use in the teens.” 
Patton et al. (2006) surveyed a random sample of young people in the state of 
Victoria, Australia. The first interview (wave 1) took place when the respondents 
were 14-15 years old; the last interview (wave 8) took place ten years later. Young 
people were asked about their consumption of cannabis, alcohol and Class A 
drugs (both frequency and quantity consumed).  
Alcohol and/or cannabis were used by close to 90% of the sample. But only a 
third progressed to the heavy-usage stage as young adults. The study finds that 
moderate48 consumption of cannabis and alcohol in teenage years was positively 
associated with heavy substance misuse in adulthood. For example: 
• 23% of persistent moderate-risk teenage cannabis users were daily cannabis 
users at wave 8 (age 24-25) and 14% were high-risk alcohol users. 
• Similarly, 10% of moderate teenage alcohol users were daily cannabis users 
and 20% were high-risk alcohol users at wave 8.49 
“High-risk cannabis use was also associated with failure in education and training, not being in 
a relationship and high rates of parenthood. It was also associated with over seven times higher 
risks of amphetamine and cocaine usage, and higher rates of consultation with drug and alcohol 
counselling services.” 
These statistics suggests that, in aggregate, 30-37% of moderate teenage 
substance misusers are likely to become heavy users by the time they reach 
adulthood. This gives us an estimate for the proportion of young people who 
might experience drug-related problems later in life if not treated. We expect this 
to be the lower bound estimate because the teenagers described in this study are 
moderate users, while those treated by the NTA tend to be heavy users. 
Therefore, the probability of having drug-related problems later in life for them is 
likely to be significantly higher. 
                                                 
47 “Teenage drinking and the onset of alcohol dependence: a cohort study over seven years” 
48 In this study, moderate alcohol users are defined as males drinking more than 28 units in the last week or 
females drinking more than 14 units in the last week. Moderate cannabis use is defined as at least weekly 
use. 
49 In this paper, high risk alcohol use is defined as men (women) drinking in excess of 43 (28) standard 
drinks 
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Class A drugs 
There exits a strand of literature developing a so called ‘gateway theory’, which 
suggests that cannabis is a ‘gateway’ drug whose usage encourages other forms of 
more serious illicit drug use (Kandel et al., 1986; Kandel, Yamagushi and Chen, 
1992; Stenbacka et al., 1993). It appears that while the use of cannabis indeed 
precedes other drug use, the causal relationship is not very strong if other factors 
are taken into account. Fergusson and Horwood (2000) tested the theory taking 
into account several other factors, such as parental criminality and drug use, peer 
group effects, etc. When these characteristics are taken into account, the effect of 
cannabis use becomes less significant. However, for those who use cannabis 50+ 
times for at least one year, the effect remains strong, i.e. these young people are 
more likely to start using other illicit substances (including heroin and crack) than 
those who do not use cannabis or use it only occasionally.  
Unfortunately, this analysis does not go as far as predicting what proportion of 
teenage cannabis users will become adult PDUs (as oppose to using Class A 
drugs occasionally). Therefore, it is of limited use for our purposes. Instead, we 
rely on the literature that focuses specifically on Class A drug users, their drug 
career progression and the probability of natural remission. 
• Hser et al. (2008) analysed the trajectories of heroin, cocaine and 
methamphetamine use. All people in their sample were persistent users over 
a ten year period. In the beginning of their drugs career, frequency of use 
was 8 days per month (for cocaine users), 12 days for meth users and 13 
days for heroin users. These figures have increased significantly for heroin 
users over time (to up to 18 days per month). Primary drug type was strongly 
associated with future trajectory, with heroin users most likely to be in the 
High Use group and cocaine and meth users most likely to be in the 
Moderate Use group. Only 5% stopped using drugs after 3-5 years. For 95% 
average consumption either increased or remained stable over the ten year 
period. This is despite the fact that some of these drug users received 
treatment. 
This statistics confirms that Class A drug users exhibit very persistent 
consumption patterns and that few users experience natural remission. 
5.2.4 Implications for our counterfactual analysis 
The young people treated by the NTA can be split into three main categories 
based on primary substance: 
à heroin and crack users – 2.4% of the sample; 
à mainly alcohol users – 36.6% of the sample. These young people may 
also use other substances, including heroin and crack (1.7%); 
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à mainly cannabis users, but also other drugs, such as cocaine, ecstasy and 
amphetamines – 60.3% of the sample. Some of these young people use 
multiple substances, including heroin and crack (1.7%). 
For each of these groups, we combine the statistics on primary substance with 
the probabilities from the literature that these young people would become 
PDUs (problematic users of heroin and crack), problematic alcohol users or 
heavy users of cannabis (non-PDUs) as adults. This is presented in Table 29 
below.  
Table 29. Probabilities of future adverse outcomes in the absence of treatment 
 Probability of becoming … 
Main substance % of the 
sample 
PDUs Non-PDUs Problematic 
alcohol users 
Heroin and crack 
users 
2.4% 95%   
Alcohol users 36.6% 1% 10% 20%-40% 
Cannabis and 
other drug users 
60.3% 1% 23% 14% 
Source: Frontier analysis based on the NDTMS/TOP, Hser et al. (2008), Filmore (1975) and Patton et al. 
(2006) 
 The interpretation of this table is as follows:  
• 2.4% of the young people in our sample are treated for heroin and crack 
misuse. According to Hser et al. (2008), almost all these young people (95%) 
are expected to become adult PDUs if not treated. It is possible that the 
remaining 5% would have problems with alcohol or other drugs. However, 
in the absence of strong evidence on this, we do not take this possibility into 
account in our quantitative analysis (hence, our estimates of the 
counterfactual costs are conservative). 
• 37% of the sample misuse alcohol. According to Filmore (1975) and Patton 
(2006), between 20% and 40% of these young people are likely to become 
problematic alcohol users as adults, if not treated. Moreover, 10% may also 
become heavy cannabis users (non-PDUs).  
Modelling progression from teenage alcohol use to adult problematic drug 
use is difficult. It requires significantly more information than is currently 
available in the NDTMS/TOP, i.e. age of initiation into drugs and alcohol, 
family characteristics, parental criminality and drug use, etc. Our estimate 
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(1%) is based purely on current use of heroin and crack by this group and 
may potentially understate the true probability that a teenage alcohol user 
may become an adult PDU if not treated. 
• 60% of the sample misuse cannabis or other drugs (cocaine, ecstasy, 
amphetamines). According to Patton et al. (2006), 23% of them are likely to 
continue their career of heavy cannabis use, while 14% are likely to become 
problematic alcohol users as adults. Transition to PDUs (1%) is based on 
current consumption of heroin and crack and may potentially understate the 
risk (i.e. our estimate is conservative).50 
Overall, we find that between 37% and 44% of the sample are expected to have 
persistent problems with drug and alcohol if not treated. Below, we establish the 
costs associated with adult substance misuse. 
5.2.5 Costs associated with adult substance misuse 
There are three types of adult substance misuse that we assign costs to in our 
model: 
à adult alcohol misuse; 
à adult problematic drug use; and 
à adult non-problematic drug use. 
In this report, we do not attempt to calculate bottom-up estimates of the cost of 
adult substance misuse. Instead, we have drawn upon previously published 
sources to estimate the lifetime cost of different types of adult substance misuse. 
This produces a range of potential estimates of the lifetime economic and social 
cost of problematic drug use (PDU), non-problematic drug use (non-PDU), and 
problematic alcohol use. As shown in section 6.2, the choice of value within this 
range can have a significant impact on our results.  
Most previous studies estimate the annual cost to society of adult drug and 
alcohol misuse. This cost can also be expressed as annual cost per substance 
misuser. Cost estimates are typically broken down into the following categories: 
à health and social care costs; 
à crime (and criminal justice system) costs; 
                                                 
50 Although our model groups cannabis users in the same category as other drug users (including cocaine, 
ecstasy and amphetamine users), we recognise that there may be differences in the likelihood of developing 
adult substance misuse problems across these groups. For example, Hser et al. (2008), indicate that young 
cocaine use will often persist into adulthood. To the extent that cocaine users are more likely than cannabis 
users to develop adult substance misuse problems, our analysis provides a conservative estimate of the 
likelihood of escalation. However, this effect is likely to be small given that relatively few young people 
receive treatment for cocaine use compared to cannabis use. 
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à the cost of lost output; and 
à the cost of drug related deaths. 
We assume that the substance abuse “career” lasts 20 years (to be consistent with 
the NTA and DH modelling). We then discount these costs over time using an 
annual discount rate of 3.5%. 
A summary of the lifetime costs of different types of adult substance misuse is 
given in Table 30. To ensure that our estimates are consistent, we report all costs 
in 2009 prices. 
Table 30. Lifetime costs of adult substance misuse 
Type of adult 
substance 
misuse 
Study Annual 
cost 
Discounted 
lifetime cost 
Range of 
discounted 
costs 
The Societal Cost of Alcohol Misuse in 
Scotland for 2007 
£16,207 £238,397 
Alcohol misuse: How much does it cost? (First 
estimate) 
£11,767 £173,090 Adult alcohol 
abuse 
Alcohol misuse: How much does it cost? 
(Second estimate) 
£12,737 £187,363 
£173,090 to 
£238,397 
The economic and social costs of Class A drug 
use in England and Wales, 2000 (High 
estimate) 
£61,109 £898,909 
The economic and social costs of Class A drug 
use in England and Wales, 2000 (Medium 
estimate) 
£52,224 £768,214 
The economic and social costs of Class A drug 
use in England and Wales, 2000 (Low 
estimate) 
£37,416 £550,388 
Adult 
problematic 
drug use 
Assessing the scale and impact of illicit drug 
markets in Scotland 
£65,184 £958,848 
£550,388 to 
£958,848 
Adult non-
problematic 
drug use 
RAND prevention costs effectiveness study   £21,300 to 
£45,100 
Source: Frontier calculations based on the Home Office and RAND publications 
Below, we expand on the evidence and detailed descriptions of the estimated 
costs of adult problematic and non-problematic drug and alcohol misuse. 
Adult alcohol abuse 
In this study, we employ a consistent definition of adult alcohol misuse that 
includes not only dependent alcohol use, but also a broader group of people who 
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consume alcohol at harmful levels. Harmful drinking is defined as when a person 
drinks over the recommended weekly amount and has experienced health 
problems directly related to alcohol.51 We do not include adults whose alcohol 
use may be defined as hazardous, as there is little evidence of the harm caused by 
this type of alcohol use.52 The definition used in this report therefore 
encompasses the majority of alcohol use that leads to physical, social or 
psychosocial harm. Furthermore, this approach mirrors the definition of 
problematic alcohol use discussed in section 5.2.3  
A Cabinet Office study53 in 2003 put the annual cost of alcohol misuse in 
England at £23bn-£26bn (in 2009 prices), which is equivalent to £11,767 - 
£12,737 per heavy adult alcohol user54 per year. As shown in Table 30, this 
equates to a discounted lifetime cost over a 20-year period of alcohol abuse of 
£173,090 (using the low estimate) to £187,363 (using the high estimate). 
Table 31 breaks down the two estimates of the cost of alcohol misuse in 
England into individual cost categories. The table shows that around two thirds 
of these costs are associated with crime, including criminal justice costs, prison 
costs, victim costs, etc. This is to be expected given a strong association between 
problematic alcohol use and violent crime. The remaining costs (c. 30%) are 
health care costs (inpatient, outpatient, A&E, GP consultations, etc.) and lost 
output (due to absenteeism). Adjusting for inflation, the total cost per heavy adult 
alcohol user in 2009 prices ranges from £11,767 (the low estimate) to £12,737 
(the high estimate), leading to the annual costs reported in Table 30 
                                                 
51 The number of people drinking alcohol at harmful levels is difficult to measure exactly, and the two 
studies described in this section use the number of men (women) who drink in excess of 43-50 (28-36) 
units of alcohol per week. as a proxy for the number of harmful adult alcohol users. 
52 See for example “The Societal Cost of Alcohol Misuse in Scotland for 2007”, York Health Economics 
Consortium, University of York, page 8 
53 Cabinet Office: Alcohol misuse: How much does it cost? September 2003 
54 In this study, heavy adult alcohol use covers men (women) drinking more than 50 (36) units per week. 
This totalled 1,930,705 in 2000-01. 
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Table 31. The economic and social cost of adult alcohol abuse in England 
Cost category First 
estimate 
Second 
estimate 
Total cost 
per heavy 
alcohol user 
(First 
estimate) 
Total cost 
per heavy 
alcohol user 
(Second 
estimate) 
Health care costs (inpatient, outpatient, 
A&E, ambulatory services, GP consultations, 
practice nurses, other primary care, 
dependency drugs and treatment services) 
£1,383m £1,683m £717 £872 
Workplace and wider economy costs (lost 
productive output due to absenteeism, 
reduced employment and premature 
mortality) 
£5,194m £6,421m £2,690 £3,326 
Crime costs (Criminal Justice System costs, 
property/health and victim services costs, 
costs in anticipation of crime, crime costs of 
lost productive output, emotional impact 
costs, drink-driving costs) 
£11,940m £11,940m £6,184 £6,184 
Total (in 2001 prices) £18,517m £20,044m £9,591 £10,382 
Total (in 2009 prices) £22,719m £24,592m £11,767 £12,737 
Source: Cabinet Office: Alcohol misuse: How much does it cost? September 2003 
A Scottish study55 in 2007 provided an alternative estimate of the cost of adult 
alcohol misuse. The contribution of each cost category to this estimate is shown 
in detail in Table 32. Lost output, alcohol-related death and crime account for 
the majority of the total cost of adult alcohol abuse in Scotland. After adjusting 
for inflation, this study estimated the cost of alcohol misuse at £3.7bn per year 
(in 2009 prices). This is equivalent to £16,207 per harmful adult alcohol user56 
per year, which is the annual figure for this study reported in Table 30. The total 
discounted economic and social cost of alcohol misuse per person over a typical 
20-year ‘career’ implied by this study is then £238,397. 
                                                 
55 The Societal Cost of Alcohol Misuse in Scotland for 2007, York Health Economics Consortium, 
University of York 
56 This report uses the number of men (women) drinking more than 50 (35) units per week as a proxy for 
the number of harmful adult alcohol users. 
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Table 32. The economic and social cost of adult alcohol misuse in Scotland 
Cost category Annual 
cost (mid-
point) 
Annual cost per 
harmful adult 
alcohol user 
Health (GP and practice nurse, Community Psychiatric Team, 
community prescribed drugs, laboratory tests, inpatients, A&E, 
outpatients, day cases, ambulance journeys, alcohol services) 
£268m £1,169 
Social care (children and families, criminal justice, care homes, 
Children's Hearing System) 
£231m £1,007 
Crime (costs in anticipation of crime, costs as a consequence of crime, 
costs in response to crime) 
£727m £3,175 
Lost productive capacity (presenteeism, absenteeism, lost 
productive capacity due to unemployment, premature mortality) 
£866m £3,780 
Wider social costs (wider costs of premature mortality, i.e. non-paid 
work, intangible human costs of alcohol-related death) 
£1,465m £6,396 
Total (in 2007 prices) £3,556m £15,527 
Total (in 2009 prices) £3,711m £16,207 
Source: The Societal Cost of Alcohol Misuse in Scotland for 2007, York Health Economics Consortium, 
University of York 
These two studies provide a range of estimates for the discounted cost per 
person of a career of adult alcohol abuse. As summarised in Table 30, these 
annual cost estimates range from £173,090 - £238,397 per adult alcohol misuser 
over a 20 year ‘career’. 
Problematic drug use 
A Home Office commissioned study57 put the cost of problematic Class A drug 
use at £29,616-£53,309 per user per year (in 2009 prices). As shown in Table 33, 
two thirds of these costs are the costs of crime, including criminal justice costs, 
prison costs, victim costs, etc. These estimates also include health care costs and 
costs associated with caring for children of PDUs. 
                                                 
57 The economic and social costs of Class A drug use in England and Wales, 2000 
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Table 33. The economic and social cost of adult problematic Class A drug use 
 Annual cost per problem Class A drug user 
 Low estimate Medium estimate High estimate 
Health costs (primary care, A&E, inpatients, 
mental health, drug-related deaths, neonatal 
services) 
£2,651 £3,977 £4,772 
Crime costs (arrest costs, custody costs, criminal 
justice costs, prison costs, victim costs) 
£20,861 £31,291 £37,550 
Other social costs (caring for children in need) £125 £187 £224 
Total (in 2000 prices) £23,637 £35,455 £42,546 
Total (in 2009 prices) £29,616 £44,424 £53,309 
Source: The economic and social costs of Class A drug use in England and Wales, 2000 
The Home Office study does not estimate lost output due to problematic drug 
use. However, the study does report that 81% of PDUs were unemployed prior 
to being admitted for treatment (vs. 5.5% for the population as a whole in 2000). 
Based on these statistics, we estimate lost output to be £7,800 per person per 
year (under a conservative assumption that if employed, PDUs would earn the 
minimum wage). Adding this to the health, crime and other social cost of 
problematic drug use in Table 33, the total annual economic and social cost of 
PDUs increases to £37,416 - £61,109 per person, depending on whether the 
high, medium, or low cost estimate is used. 
A 2009 Scottish study also estimated the annual cost to society per problem drug 
user. This study did include the cost of lost output, as well as health, crime and 
other social costs. This resulting cost per problem drug user was estimated at 
£65,184 per year (in 2009 prices), higher than the England and Wales study and 
therefore representing the upper bound in the lifetime cost of adult problematic 
drug use. 
These annual costs are equivalent to £550,388 - £958,848 over a 20 year drug 
career, depending on the study and estimate used. These figures are broadly 
consistent with NICE estimates of the lifetime crime cost (£445,000) and 
healthcare cost (£35,000) for injecting drug users, which in turn have been used 
in recent work carried out by the NTA in their analysis of the costs of adult 
problematic drug use58. Whilst the estimates used by the NTA are at the lower 
end of our range of lifetime costs, there are other costs included Table 33 not 
                                                 
58 NICE (2009) “Costing statement: Needle and syringe programmes” 
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captured by the NTA work, which would tend to bring these cost estimates more 
in line with each other. 
Non-problematic adult drug use 
We are unaware of any research into the costs of non-problematic drug use 
conducted in the UK In our work we rely on a study of cost-effectiveness of 
school-based prevention programs in the US.59 This study focuses on cocaine 
users and estimates that total costs associated with cocaine consumption in 1999 
were $27 billion, including the costs of crime, health and reduced productivity.60  
It is assumed that these costs are broadly proportional to cocaine consumption. 
Life-long consumption per person is estimated to be between 225 gm and 475 
gm. This corresponds to $32,000 - $67,60061 or £21,300 - £45,100 (in 2009 
prices). 
Costs of non-problematic drug use appear to be significantly lower than the costs 
associated with problematic drug use and problematic alcohol use. This makes 
intuitive sense given that PDUs and problematic alcohol users are more likely to 
be involved in violent crimes and are more likely to have serious health problems 
(including dying prematurely).  
To summarise, our estimates of the lifetime costs of adult substance misuse are 
as follows: 
à £173,090 - £238,397 for adult problematic alcohol users; 
à £550,388 - £958,848 for PDUs; and 
à £21,300 - £45,100 for non-PDUs. 
5.2.6 Estimates of long-term costs associated with young people’s substance 
misuse 
We now combine the lifetime costs of adult substance misuse (discussed above) 
with the probabilities that young people currently in treatment would have 
become adult problematic and non-problematic drug users in the absence of 
treatment (presented in Section 5.2.4). The results of the counterfactual cost 
calculations are presented in Table 34 below. 
Total counterfactual costs are estimated to be between £1.1 billion and £2.2 
billion. These are estimated as: 
                                                 
59 “An ounce of prevention: a pound of uncertainty”, RAND, 1999 
60 We do not include any additional costs of being NEET in this case, as lower productivity and earnings 
potential has already been taken into account in these estimates of the cost of non-problematic drug use. 
61 Economic and social costs associated with consumption of one ton of cocaine are estimated to be $93 
million (in 1992 prices). 
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where N=24,053 (the number of young people in treatment),  
iα - shares of the sample according to the primary substance i (heroin & crack, 
alcohol, cannabis),  
ijβ - probability of a future outcome j (PDU, non-PDU, problematic alcohol use) 
based on primary substance i;  
jCost - lifetime cost of being PDU, non-PDU, problematic alcohol user. 
Table 34. Total counterfactual costs 
 Probability of becoming … 
Main substance % of the 
sample 
PDUs Non-
PDUs 
Problematic 
alcohol user 
Class A drug users 2% 95%   
Alcohol users 37% 1% 10% 20%-40% 
Cannabis and other drugs 60% 1% 23% 14% 
 
Unit life-time costs £550,388 
– 
£958,848 
£21,300 –
£45,100 
£173,090 – 
£238,397 
 
Total counterfactual costs £1.1 billion - £2.2 billion 
Total counterfactual costs (per person) £46,145 - £91,964 
Source: Frontier analysis based on the NDTMS/TOP, Hser et al. (2008), Filmore (1975) and Patton et al. 
(2006) 
These costs are equivalent to £46,145 - £91,964 per person. It is worth noting 
that these average costs are lower than the unit costs of being a PDU or a 
problematic alcohol user. This is because some young people (between 56% and 
64% of the sample) are expected to experience natural remission (‘grow out’ of 
their habit) and, therefore, not incur these costs in the future. In addition, 17.5% 
of the sample are expected to become non-PDUs (if not treated), with the costs 
of non-PDU being somewhat lower – between £21,300 and £45,100 over a 20 
year period. 
In section 6 below, we estimate the extent to which these costs can be reduced as 
an outcome of the young people’s specialist treatment. 
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6 Estimating the benefits of young 
people’s specialist treatment 
In this section, we explain how we have measured the impact of treatment on the 
immediate and long-term costs of young people’s drug and alcohol misuse. We 
then complete the CBA by comparing the costs and benefits of treatment under 
a range of different assumptions. 
6.1 Immediate benefits 
First, we describe the data we have used to estimate the immediate impact of 
treatment, and present some important caveats surrounding this data and how it 
can bee used. Second, we summarise what the data shows on the potential impact 
of treatment on crime and health costs. Finally, we describe the potential 
uncertainty surrounding these estimates, and discuss the required impact that 
treatment needs to have on immediate outcomes for it to be cost effective. 
6.1.1 Data used to estimate immediate benefits 
In 2007, the NTA developed a tool which would help monitor and assess the 
effectiveness of the national drug and alcohol treatment system, known as the 
Treatment Outcome Profile (“TOP”). The TOP replaced proxy measures of 
treatment effectiveness (such as waiting times and treatment retention) with a 
more focused, outcome-based set of measures on the effectiveness of drug and 
alcohol treatment. The TOP was initially developed for adult drug treatment, but 
has subsequently been introduced for 16 and 17 year olds. 
TOP data is recorded at key points within an individual’s treatment path: 
à at the start of treatment; 
à every six months from then on; and 
à when young people exit treatment.62 
At each stage, young people are asked a number of questions by treatment 
workers about their substance use, and other aspects of their behaviour such as 
crime, health, housing, employment and education. The questions asked in the 
TOP are presented in detail in Annexe 1. The results are then submitted to the 
NTA where they are validated and analysed before being fed back to local 
commissioners and providers. 
                                                 
62 For most young people’s treatment, the length of time spent in treatment is relatively short. We are 
therefore only able to compare TOP data when entering treatment, with TOP data when leaving treatment 
in this study. 
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To estimate the immediate benefits of treatment in this study, we compare the 
behaviour of young people before treatment with the behaviour of the same 
group of young people when they leave treatment. Then, taking behaviour prior 
to treatment as a proxy for what would have happened in the absence of 
treatment, we can assess the effectiveness of treatment in changing behaviour. 
We have considered the TOP data on young people aged 16-17 who left 
treatment in the first quarter of 2010/11. There are some important caveats to 
note before using this data. 
• The data only covers 16-17 year olds in treatment. TOP data is not 
collected for young people under 16. A comparison of outcomes before and 
after treatment should therefore only be applied to 16-17 year olds in our 
sample. However, although the level of crime may vary by age, we have 
found no evidence to suggest that the impact of treatment on crime 
committed by 16-17 year olds will be proportionally different from impact 
on crime committed by young people under 16. We have therefore chosen 
to apply the observed reductions in crime to all young people in our sample. 
• The data only covers planned treatment exits. It is also important to 
consider unplanned exits by young people from treatment, which accounted 
for 32% of planned and unplanned exits in 2008-09. There are several 
assumptions we can make on the benefit for those with unplanned exits 
from treatment. At the most conservative, we can assume that young people 
with unplanned exits from treatment will receive no immediate benefit of 
treatment. However, young people who do not complete treatment may 
benefit considerably as a result of the treatment they had received up to that 
point. The least conservative estimate would attribute the same benefits to 
young people regardless of whether their treatment exit was planned or 
unplanned. We will model a number of scenarios within this range of 
impacts. 
• TOP data is not available for everyone. There were 1,359 16-17 year olds 
who left treatment over this period. However, before and after TOP data 
was only recorded in 1,055 cases, or for 78% of treatment exits over the 
period. Whilst we note that this is not full coverage of those leaving 
treatment, the sample size remains sufficiently large to give us confidence in 
the results. We have seen no evidence to suggest that impact of treatment 
for young people where TOP data before and after was not recorded would 
be any different. 
Despite these limitations, TOP data has a significant advantage over other data 
sources in that it concentrates solely on a subset of young people who receive 
treatment. This group is the focus of our study. It is also a direct measure of 
outcomes, particularly for crime, as it records the level of problematic behaviour 
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directly, rather than by inferring the change in problematic behaviour from other 
measures of effectiveness. We therefore believe that it is appropriate to use this 
TOP data to give us an idea of the potential impact of treatment on outcomes 
for young people. 
6.1.2 Immediate impact of treatment from TOP data 
Table 35 shows percentage change in crime and drug/ alcohol related health 
episodes before and after treatment. We use these as a proxy for the treatment’s 
short-term effectiveness. 
Table 35. Impact of treatment on immediate crime and health costs 
Adverse outcome Percentage reduction for young 
people in treatment 
Level of assaults* 61% 
Level of theft* 55% 
Amount of shoplifting* 64% 
Alcohol related episodes and deaths 39% 
Drug related health episodes and deaths 42% 
Source: Frontier analysis 
Notes: * Assumes half the reduction in crime for those with unplanned exits compared to those with 
planned exits. 
The way in which these estimates have been calculated is described in more detail 
below. 
Crime 
As we have noted previously, the TOP data on crime reports the following three 
measures. 
à Whether or not the young person had committed an assault in the past 
28 days. 
à Whether or not the young person had committed a theft in the past 28 
days. 
à The number of days in the past 28 days that young people have 
committed a shoplifting offence. 
As shown in Table 36, 9.2% of 16-17 year olds with a planned treatment exit 
reported that they had committed an assault in the 28 days prior to entering 
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treatment. When leaving treatment, just 2.5% of the same group of young people 
had committed an assault in the past 28 days. For those with a planned treatment 
exit, this therefore equates to a 73% reduction in the number of assaults over the 
treatment period. However, planned treatment exits account for 68% of planned 
and unplanned treatment exits. For the remainder of young people with unplanned 
exits, we have assumed that the reduction in the number of assaults is half the 
reduction for young people with planned exits (i.e. a 37% reduction)63. 
Estimating a weighted average reduction in the number of assaults across both 
planned and unplanned treatment exits, the number of assaults for all young 
people fell by 61% during treatment.64 
A similar change post-treatment can be observed for the proportion of young 
people who committed thefts. 6.8% of young people in treatment reported 
committing theft (not including shoplifting) in the month before entering 
treatment, compared to 2.4% of young people leaving treatment. For those with 
a planned treatment exit, this equates to a reduction of 65% when in treatment. 
Again, assuming that the reduction in the amount of theft committed by young 
people with unplanned treatment exits is half the reduction seen for those with 
planned exits; this equates to a 55% reduction in theft across all those in 
treatment, as shown in Table 36. 
                                                 
63 Below we consider alternative scenarios – no impact for unplanned exits and the same impact as for 
planned exits. 
64 Calculated as follows: (68% planned exits x 73% reduction) + (32% unplanned exits x ½ x 73% 
reduction) = 61% reduction 
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Table 36. TOP data on assaults and thefts pre and post-treatment 
 Percentage of young people in TOP data who 
reported committing a theft or an assault in 
the past 28 days 
 
 Prior to entering 
treatment 
When leaving 
treatment 
Percentage 
reduction 
Assault 9.2% (143) 3.5% (55) 61% 
Planned exits 9.2% (97) 2.5% (26) 73% 
Unplanned exits 9.2% (46) 5.8% (29) 37% 
Theft 6.8% (106) 3.1% (48) 55% 
Planned exits 6.8% (72) 2.4% (25) 65% 
Unplanned exits 6.8% (34) 4.6% (23) 33% 
Source: Frontier analysis of TOP data 
Note: Figures in parenthesis denote the number of people in each group in the TOP data 
The TOP data on the level of shoplifting before and after treatment is recorded 
slightly differently. 5.5% (58 people) aged 16-17 reported engaging in shoplifting 
in the month before entering treatment. On average, those who did report 
shoplifting at the start of treatment did so on 5.1 days over the past 28. When 
leaving treatment, the average number of days of shoplifting for this group had 
fallen to 1.2. The amount of shoplifting therefore falls by 76% for this group.65 
Assuming for unplanned exits that the reduction in the amount of shoplifting is 
half this (i.e. 38%), the overall reduction in the number of days shoplifting by 
young people when in treatment is 64%. 
It should be noted at this point that not all reductions in crime can be attributed 
solely to drug and alcohol treatment. Many young people referred from the 
criminal justice system will continue to be under Youth Offending Team 
supervision or receive other interventions aimed specifically at tackling their 
offending. We may therefore overestimate the contribution of treatment to 
reductions in offending behaviour. However, this should be considered in light 
                                                 
65 0.7% of 16-17 year olds (7 people) who were not engaging in shoplifting at the start of treatment did 
report that they had shoplifted at the end of treatment. This would suggest that treatment has led to an 
increase in their shoplifting behaviour. However, we would argue that shoplifting by these individuals is 
likely to be infrequent, and not a direct consequence of the treatment they receive. We have therefore not 
included these individuals in our analysis of the effectiveness of treatment on criminal behaviour. 
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of the conservative approach we have taken when estimating the overall levels of 
offending by young people in treatment. 
Health 
The TOP records a measure of the health of young people based on a self-
reported score from 1-20 covering (i) physical health; and (ii) psychological 
health. The TOP data before and after treatment shows that for young people 
with planned exits, the mean self-reported physical health score improved from 
13.7 prior to treatment, to 15.4 when leaving treatment, an improvement of 13%. 
The mean psychological health score increased from 12.5 to 15.3, an 
improvement of 22%. 
The evidence from TOP therefore shows that there is some improvement in 
health outcomes following treatment. However, it is not possible to translate 
these improvements in self-reported health scores into a measurable reduction in 
health care costs. 
When we calculate health care costs in the counterfactual, we only include costs 
which can be wholly attributed to drug or alcohol misuse. It could be argued that 
the health care costs directly associated with drug and alcohol use fall to zero if a 
young person leaves treatment free of drug or alcohol use66. More generally, it is 
reasonable to think that the level of these costs relates directly to the extent and 
frequency of drug and alcohol use. 
The TOP data contains two pieces of information on the level of drug use by 
young people when entering and when leaving treatment. First, the TOP records 
the proportion of young people using a drug when entering treatment who are 
abstinent from that drug when they leave treatment. Abstinence is defined as not 
using the drug in any of the 28 days prior to the interview. Second, the TOP data 
compares the mean number of days that a drug is used at the start of treatment, 
with the mean number of days of drug use when leaving treatment. 
To measure the proportion of health care costs directly related to drug and 
alcohol misuse that can be avoided through treatment, our preferred approach is 
to compare the number of days of use before and after treatment. This will not 
only capture a change in outcomes for young people who become abstinent, but 
also captures improvements in outcomes for young people whose substance 
misuse is significantly reduced. 
Alcohol users on average drank on 8 days per month prior to entering treatment. 
When the same group left treatment, they drank on 4.2 days, a 47% reduction. 
The extent of the reduction in drug use post-treatment varied widely across 
drugs, with a greater than 90% reduction in the number of days of opiates or 
                                                 
66 This would be true only if there were no persistent effects on the health of an individual from young drug 
and alcohol use. 
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amphetamines use, but only a 46% reduction in the number of days of cannabis 
use. Given that cannabis use was far more common amongst those in treatment, 
the weighted average reduction in the mean number of days of drug use during 
treatment was 50%. 
Again, we have assumed that reductions in drug use for young people with 
unplanned exits from treatment were half the size of the reductions for young 
people with planned exits. Across both planned and unplanned exits, the 
reduction in days of alcohol use was therefore 39%, and the reduction in days of 
all other drug use was 42%. If we assume that the number of days of drug and 
alcohol use is directly proportional to the number of drug and alcohol related 
illnesses and deaths, then we can model the reduction in health care costs during 
treatment using these figures. 
6.1.3 Quantifying the benefit of treatment 
If we apply the estimated reductions in crime and health costs summarised in 
Table 35, to the cost of these problems in the counterfactual, this gives an 
estimate of the potential economic and social cost savings from treatment. 
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Table 37. Central case estimates of the immediate annual net benefit of treatment 
Cost area Counterfactual 
cost per year 
Reduction in cost 
post-treatment 
Net benefit 
of treatment 
Shoplifting £18.4m 64% £11.7m 
Theft £22.2m 55% £12.1m 
Assault £57.6m 61% £35.4m 
Crime total £98.2m  £59.3m 
Drug related mental health 
and behavioural disorders £36,768 42% £15,330 
Poisoning by drugs £20,780 42% £8,664 
Alcohol-related NHS 
hospital admissions £50,976 39% £19,930 
Inpatient subtotal £108,524  £43,923 
Drug related deaths £4.1m 42% £1.7m 
Alcohol related deaths £0.1m 39% £0.04m 
Drug and alcohol deaths 
subtotal £4.2m  £1.7m 
Health care total £4.3m  £1.8m 
All immediate benefits 
(crime plus healthcare) £102.5m  £61.1m 
Source: Frontier analysis 
6.1.4 Sensitivities 
One assumption we have made that could potentially affect the size of the net 
benefit of treatment is the level of benefits that we attribute to young people with 
unplanned exits from treatment. In the previous table, we present our central 
case estimates based on a reduction in crime and drug use which is half of the 
reduction observed for young people with planned treatment exits. 
The table below shows how the calculated immediate net benefits of treatment 
change under two extreme scenarios: 
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à first, if we attribute no improvement in outcomes to young people 
with unplanned treatment exits; and 
à second, if we attribute the same improvement in outcomes to young 
people with an unplanned treatment exit. 
Table 38. Immediate annual net benefit of treatment – unplanned treatment exit 
scenarios 
Cost area No improvement 
for unplanned 
exits 
Half of the 
improvement for 
unplanned exits 
The same 
improvement for 
unplanned exits 
Shoplifting £9.5m £11.7m £14.0m 
Theft £9.8m £12.1m £14.5m 
Assault £28.6m £35.4m £42.2m 
Crime total £47.9m £59.3m £70.6m 
Drug related mental 
health and behavioural 
disorders 
£12,396 £15,330 £18,264 
Poisoning by drugs £7,006 £8,664 £10,332 
Alcohol-related NHS 
hospital admissions £16,116 £19,930 £23,744 
Inpatient subtotal £35,517 £43,923 £52,329 
Drug related deaths £1.4m £1.7m £2.0m 
Alcohol related deaths £0.03m £0.04m £0.04m 
Drug and alcohol 
deaths subtotal £1.4m £1.7m £2.1m 
Health care total £1.4m £1.8m £2.1m 
All immediate benefits 
(crime plus healthcare) £49.4m £61.1m £72.8m 
Source: Frontier analysis 
The range of annual net benefits from changing this assumption is therefore 
relatively large, ranging from £49.4m to £72.8m, with a central case estimate of 
£61.1m. However, even under the most conservative assumption, the immediate 
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net benefit of treatment is roughly equal to the annual amount spent on drug and 
alcohol treatment for young people. 
6.1.5 Required reductions for treatment to be cost effective 
As shown in Table 37, our central case estimate of the immediate benefits of 
treatment is an annual cost saving of £61.1m. Over the two year period for which 
we estimate immediate benefits, the discounted net present value of these savings 
is £120.1m. In comparison, the amount spent on young people’s treatment in 
2008-09 was £62.2m. Overall, the immediate benefits of young people’s 
treatment, even without taking into account the potential long-term benefits of 
treatment, is almost double the total annual treatment costs. 
The majority of these immediate benefits come from reductions in the amount of 
crime committed by young people following treatment. £59.3m of the £61.1m of 
savings, or 97% of savings come from reductions in the amount of theft, 
shoplifting and assault committed by young people who misuse drugs and 
alcohol. 
One question which may be of interest to policy makers and treatment providers 
is “what is the minimum reduction in the amount crime committed by young 
people in treatment in order for the treatment to be cost effective?” This 
question does not include the potential immediate benefits from lower health 
care costs, or the long term benefits of treatment. 
The table below shows that a 32% reduction in all types of crime committed by 
young people in treatment is required in order for the treatment provided to be 
cost effective over a two year period, even without taking into account the size of 
any long term benefits. As described earlier in this chapter, TOP data indicates a 
50-65% reduction in the amount of crime committed compared to pre-treatment 
levels. Given this observed reduction, a 32% reduction in the amount of crime 
committed post-treatment appears achievable. 
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Table 39. Immediate net benefit of treatment with a 32% reduction in all types of 
crime 
Cost area Net benefit in 
year 1 
Net benefit in 
year 2 
Total net benefit 
Shoplifting £5.9m £5.7m £11.6m 
Theft £7.1m £6.9m £14.0m 
Assault £18.6m £17.9m £36.5m 
Crime total £31.6m £30.6m £62.2m 
Source: Frontier analysis 
6.2 Long term benefits 
Unlike the immediate benefits of treatment, the long-term benefits are very 
difficult to assess. The NDTMS/TOP data includes information on a range of 
outcomes immediately after treatment, such as substance use, education and 
employment, crime and health (discussed in detail above). These immediate 
impacts, however, cannot be easily ‘translated’ into long-term effects, as some of 
those who stop using drugs immediately after treatment may relapse in a few 
months (or a few years), and incur the long-term costs associated with adult 
substance misuse. 
The same generally applies to most existing studies on treatment effectiveness, 
i.e. they focus on the immediate impacts (up to 12 months after treatment). Some 
prevention studies67 looked at the long-term effects of prevention. These studies, 
however, are fundamentally different as they assess the impact of a delay in drug 
initiation rather than the impact of young people’s treatment on the likelihood of 
persistent drug-related problems in adulthood. 
6.2.1 Re-presentation rates 
One potential way of assessing the long-term effectiveness of treatment is to use 
‘re-presentation’ rates, i.e. to look at the number of people who require a 
repeated treatment some time after their first treatment. This is the approach 
used by the NTA in the cost-benefits analysis of adult drug treatment. It is 
assumed that those who do not re-present (either voluntarily or through the 
Criminal Justice System) have recovered.  
                                                 
67 See for example “An ounce of prevention: a pound of uncertainty: the cost-effectiveness of school-based 
drug prevention programs”, RAND, 1999 
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The re-presentation rates for adults is around 50% (41% for those who exit 
treatment in a planned way compared to 53% for those who leave before 
treatment is completed). In comparison, the re-presentation rates for young 
people four years after treatment are: 
à 40% for heroin or crack users68; 
à 16% for alcohol users; 
à 17% for cannabis users. 
The re-presentation rates for young Class A drug users are comparable to adult 
PDU re-presentation rates, while the rates for young alcohol and cannabis users 
are significantly lower – 16%-17%. This is to be expected given that these young 
people, in most cases, have not yet developed substance dependency. 
We can use these re-presentation rates to assess treatment’s effectiveness, i.e. we 
can compare them against long-term substance misuse rates expected without 
treatment - 37%-44% (discussed in Section 5.2.4). Clearly, the re-presentation 
rates compare favourably, indicating that the treatment is effective for many 
young people. 
However, we need to exercise caution when using these re-presentation rates as a 
proxy for the treatment’s effectiveness. Indeed, they are likely to represent an 
upper bound on treatment effectiveness, with the actual effectiveness being 
potentially somewhat lower. This is because some young people may relapse after 
the period covered by the re-presentation data. Others may have developed 
problematic drug or alcohol use again, but without re-accessing treatment. 
Therefore, in our hypothetical scenarios below, we use slightly lower 
effectiveness rates - 7% and 10% - than those suggested by the 4 year re-
presentation rates (20%). 
6.2.2 Long-term benefits: break-even scenario 
In the absence of concrete evidence on long-term effectiveness of young people’s 
treatment, we adopt a scenario-based approach. First, we estimate a reduction in 
the long-term counterfactual costs needed in order for the benefits to counteract 
the costs. This scenario is presented in Table 40 below. 
                                                 
68 If we were instead to consider a broader group of drugs including heroin, crack, cocaine, amphetamines 
and ecstasy, the re-presentation rate for young people falls to 28%. This indicates that re-presentation 
amongst those using cocaine, amphetamines or ecstasy is lower than for heroin or crack. users. 
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Table 40. Cost-benefit analysis: break even scenario 
 Lower bound Upper bound 
Long term counterfactual costs £1,100m £2,200m 
Cost of treatment £62.2m £62.2m 
Reduction in counterfactual 
costs required to break even 
5.6% 2.8% 
Source: Frontier Economics 
We find that the long-term counterfactual costs need to be reduced by 2.8% 
(using the upper bound cost estimate) or by 5.6% (using the lower bound cost 
estimate) in order to generate the £62.2m of savings required to break even. It 
should be noted that this is the required reduction assuming no immediate 
benefit of treatment, which in practice will not be the case. 
The long-term counterfactual costs were estimated in Section 5.2. There we 
discussed that only a proportion of young people (37%-44%) are expected to 
incur these costs69. Therefore, when we estimate the number of people whose 
long-term drug taking careers are averted as a result of treatment, we need to 
keep in mind that 56%-63% of these young people are expected to have 
remission even without treatment. 
If the number of young people who are expected to become problematic adult 
drug or alcohol users reduced by 298 (using the high counterfactual cost 
estimate) or by 499 (using the low counterfactual cost estimate), this would 
deliver sufficient benefits to counteract the costs of treatment.70 This is in 
addition to 56%-63% of those who are expected to experience natural remission. 
Therefore, even if the young people’s specialist treatment delivers relatively 
modest long-term results, the benefits associated with treatment are likely to 
meet or even exceed the costs of treatment. 
6.2.3 Long-term benefits: positive net benefits 
In addition to the ‘break even’ scenario, we consider two other hypothetical 
scenarios: 
                                                 
69 The remaining 56% - 63% are expected to experience natural remission. However, when young people are 
referred to treatment, it may be difficult (or even impossible) to tell who will experience natural remission 
later and who won’t. Therefore, all young people who are referred need to be treated. 
70 Overall, the number of young people in treatment expected to become problematic adult drug or alcohol 
users ranges from 8,900 when only 37% of young people develop problems; to 10,583 if 44% of young 
people go on to develop problems as adults. 
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à 7% reduction in the number of those who are expected to have long-
term drug/alcohol related problems in adulthood; and 
à 10% reduction in the number of those who are expected to have long-
term drug/alcohol related problems in adulthood. 
These are summarised in Table 41. 
Table 41. Hypothetical scenarios of long-term cost effectiveness 
 Scenarios 
Number of people in treatment 24,036 
Number of those who are 
expected to have long-term 
drug related problems 
8,900 – 10,583  
(37%-44% of those in treatment) 
Long-term counterfactual costs £1.1 billion – £2.2 billion 
 
Scenario 1: Break-even Reduction in the number of long term users: 
between 298 and 499 
Net benefits = 0 
Scenario 2: 7% reduction in the 
number of those who are 
expected to have long-term 
drug related problems 
Reduction in the number of long term users: 
 between 622 and 740 
Net benefit = £15.5 million – £92.6 million 
Scenario 3: 10% reduction in 
the number of those who are 
expected to have long-term 
drug related problems 
Reduction in the number of long term users: 
 between 889 and 1,058 
Net benefit = £48.8 million – £159.0 million 
Source: Frontier Economics 
If these reductions (7%-10%) are achieved, the long-term net benefits of 
treatment would be high – up to £159.0 million.  
Obviously, it is difficult to measure the long-term effectiveness accurately (as it 
requires long-term follow up). However, these 7-10% reductions appear to be 
achievable given that the upper bound on treatment’s effectiveness is 20% (based 
on the 4 year re-presentation rates discussed above). 
6.2.4 .Long-term educational benefits 
In addition to the long-term treatment benefits associated with preventing adult 
problematic drug and alcohol abuse, there are further long-term benefits of 
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treatment for young people through improvements in educational and 
subsequent employment outcomes. 
There is some support in the academic literature for the positive impact that drug 
treatment can potentially have on educational attainment and hence wages. A US 
study by Register et al (2001) estimated that adolescent drug use has a significant 
negative impact on educational attainment71. In particular, they find that 
adolescent drug use reduces educational attainment by around one year, all else 
equal. 
As discussed in section 5.2.1, the lifetime cost of being NEET (expressed as a net 
present value of future costs) is between £92,000 and £356,000 per person. 
Evidence from the NDTMS suggests that 45% of young people entering drug 
treatment were NEET, compared to 9% of young people in the population as a 
whole. 
The information in the Treatment Outcomes Profile compares the number of 
young people in education and in paid work at the start of treatment and at the 
end of treatment. Table 42 summarises the information recorded in the TOP. 
Table 42. Treatment Outcomes Profile – Education and employment 
 Number at 
start of 
treatment 
% of sample 
at start of 
treatment 
Number at 
end of 
treatment 
% of sample 
at end of 
treatment 
Paid work 166 16% 220 21% 
Education 558 53% 526 50% 
NEET * 331 31% 309 29% 
Total 1,055 100% 1,055 100% 
Source: Frontier analysis of National Treatment Agency Treatment Outcomes Profile data 
Note: * The total figure assumes that young people are either in education, or in employment, and that it is 
not possible for a young person to be in both education and paid employment. As discussed below, the 
table may therefore understate the proportion of the sample that is neither in education nor employment. 
Compared to when they enter treatment, more young people are in paid work, 
but fewer young people are in education when they leave treatment. This pattern 
is to be expected as the sample in the TOP data only covers 16-17 year olds 
entering treatment. Between entering and completing treatment, at this age young 
people may have completed their education and sought to find employment. This 
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can explain the decrease in the proportion of young people in education post-
treatment. This finding also says little about young people’s level of engagement 
in education. It may be that they attend rarely or are temporarily suspended from 
school. However, in our data they would still appear to be in education at 
treatment start. Again, as we are unable to distinguish this within the data, we 
adopt a cautious approach that may underestimate rather than overstate the 
benefits of treatment. 
The TOP data before and after treatment does not directly record the number of 
young people that are NEET. In the table above, we have assumed that young 
people are either in paid work, in education, or are NEET. The data does not 
allow us to determine the number of young people who are in both education and 
employment. Young people in both employment and education are therefore 
counted twice in the above data. The resulting estimate that 31% of young 
people are NEET when entering treatment will therefore understate the true 
proportion of the sample that is NEET. 
Despite this limitation, the overall effect of treatment appears to be to reduce the 
proportion of people who are NEET from 31% of the sample, to 29% when 
leaving treatment. This is a reduction of 6.5% from the levels when entering 
treatment. 
To calculate the long-term educational and employment benefits of treatment, we 
have again adopted a scenario based approach. In particular, we have modelled 
the effect of reducing the proportion of young people who are NEET when 
entering treatment by 5%, 7.5% and 10%. As a central case, we have however 
taken the estimates reduction of 6.5% implied by the TOP data. Using the 
estimates of the lifetime cost of being NEET described above, the benefit per 
person and in total of treatment can then be calculated for our sample of young 
people entering treatment in 2008-09. 
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Table 43. Net present value of the long-term educational and employment benefits of 
treatment 
Average benefit per person Total benefit Reduction in 
the proportion 
of young 
people that are 
NEET 
Low High Average Low High Average 
5% £2,070 £8,010 £5,040 £49.8m £192.7m £121.2m 
6.5% £2,707 £10,473 £6,590 £65.1m £251.9m £158.5m 
7.5% £3,105 £12,015 £7,560 £74.7m £289.0m £181.8m 
10% £4,140 £16,020 £10,080 £99.6m £385.3m £242.5m 
Source: Frontier analysis 
The long-term educational and employment benefits of treatment are significant, 
adding a further £158.5 million (in NPV terms) to the long-term benefits of 
treatment in the central case. This central case takes an average of the low and 
high costs associated with being NEET, and applies a reduction in the 
proportion of young people that are NEET of 6.5%. Even in this central case, 
the benefits associated with reducing the proportion of young people that are 
NEET are sufficient on their own (i.e. without considering immediate or other 
long-term benefits) to outweigh the annual cost of providing specialist treatment 
services to young people. 
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7 Conclusions 
In this study, we have focussed on the costs and benefits of providing specialist 
drug and alcohol treatment services for young people. The study has shown that 
the benefit to society of providing such treatment is likely to significantly 
outweigh the cost of its provision. Furthermore, the results in the previous 
chapter indicate that the immediate benefits of treatment (i.e. until young people 
reach the age of 18) are sufficiently large alone to offset the cost of providing the 
treatment. Added to this, the long term benefits of treatment (in terms of 
improved employment prospects and reduced likelihood or become an adult 
problematic drug or alcohol user) further increase the ratio of benefits to costs. 
This chapter is divided into two sections. 
• First, we discuss our findings on the cost of treatment and the likely level of 
immediate and long-term benefits. 
• Second, we recap some of the key sensitivities in our quantitative evaluation, 
and describe how our work can be thought of as a conservative estimate of 
the likely benefits of treatment. 
7.1.1 The costs and benefits of treatment 
The cost of treatment 
In total, £62.2m was spent on specialist drug and alcohol services for young 
people in 2008-09. Approximately 40% of funding came from the Young 
People’s Pooled Treatment Budget. The remainder of the funding was provided 
in the form of Area Based Grants or Youth Justice Board funding streams. 
Immediate benefits of treatment 
This report has considered two sources of immediate benefits of drug and 
alcohol treatment for young people: reductions in criminal activity; and 
reductions in drug related deaths and health care costs directly associated with 
their substance use. Observed reductions in the level of drug-related crime post-
treatment could potentially save £59.3m per year across the 24,000 young people 
receiving treatment. Reductions in inpatient costs were minimal, but reductions 
in drug-related deaths led to further savings of £1.8m per year. The total 
immediate annual benefit of treatment across both crime and healthcare was 
therefore £61.1m. 
Given that young people on average enter treatment aged 16, and that the 
immediate benefits of treatment for young people persist for a further two years 
until the individual turns 18 (after which point the economic and social costs of 
their substance misuse are captured in our estimates of the cost of adult 
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substance misuse), our estimate of the immediate benefit of treatment includes 
two years worth of savings. This is nearly double the £62m cost of providing 
treatment for these individuals. 
Long-term benefits of treatment 
The long term benefits of treatment are more difficult to estimate than the 
immediate benefits. This is because calculating long term benefits necessarily 
involves a hypothetical assessment of the likely outcomes for individuals in the 
event that they did not receive treatment. 
If treatment leads to a 10% reduction in the number of young people who 
become problematic drug and alcohol users as adults, the potential lifetime net 
annual benefit of treatment ranges from £49 million-£159 million. For treatment 
to be cost effective, long-term counterfactual costs alone must fall by 2.8%-5.6% 
(depending on whether the high or low counterfactual cost scenario is adopted), 
equivalent to a reduction of 298-499 people who develop adult drug or alcohol 
problems. 
If treatment also successfully reduces the number of young people who are not in 
education, employment or training, we estimate that there may be further long-
term benefits. These benefits are significant and range from £121m-£242m 
depending on the reduction in the percentage of young people who are NEET. 
We have chosen a central case estimate based on our analysis of the TOP data 
which at £160m is at the conservative end of this range. 
Table 44 summarises our results and brings together both estimates of 
immediate and long-term benefits. 
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Table 44. Summary of costs and benefits 
Benefits Per 
person 
Per year 
for all 
young 
people in 
treatment 
in 2008-08 
Across a lifetime 
of substance 
misuse for all 
young people in 
treatment in 2008-
09 
Ratio of 
benefits to 
costs 
Total costs per year  £62.2m  
Immediate benefits £2,539 £61.1m £120.1m £1.93 
Crime £2,464 £59.3m £116.5m £1.87 
Health £74 £1.8m £3.5m £0.06 
Long-term benefits - - £170.0m - £401.5m £2.73 – £6.45 
Education and 
employment 
- - £121.2 - £242.5m £1.95 - £3.90 
Adult problematic 
substance misuse 
- - £48.8m – £159.0m £0.78 – £2.56 
Total benefits - - £290.1m - £521.6m £4.66 – £8.38 
Source: Frontier analysis 
The table above implies a benefit of £4.66-£8.38 for every £1 spent on young 
people’s drug and alcohol treatment. Although this estimate is presented as a 
wide range of values, the magnitude of the estimated benefits is consistent with 
previous evaluations of the cost effectiveness of adult drug treatment.  
The above results clearly show that treatment results in a net benefit, both in the 
short and long-term. In the short term, the benefits can be largely attributed to 
the immediate impact of reductions in offending, which are sufficiently large on 
their own to offset the cost of providing treatment for these young people. 
However, even if we were to assume that there is no immediate benefit of 
treatment, the long-term benefits of treatment alone remain sufficiently large to 
generate positive a net benefit in excess of treatment costs. This is true even 
using the most conservative set of assumptions. In the longer-term, this benefit 
comes from two sources. First, treatment halts the escalation of young people’s 
substance misuse and prevents subsequent problems as adults. Second, treatment 
has a significant impact in reducing the lifetime ‘scar’ on earnings associated with 
poor education and employment outcomes during adolescence. 
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7.1.2 Sensitivities 
We have based our quantitative analysis on a sample of approximately 24,000 
young people who received specialist treatment in the UK in 2008-09. These 
young people were assessed when entering and leaving treatment, and 
information on these individuals is recorded by the NTA via the National Drug 
Treatment Monitoring System. In addition to the NDTMS data, we have also 
drawn on information from published statistics and from academic research 
when calculating the immediate and long term benefits of treatment. 
Although our quantitative estimates take the best and most up-to-date evidence 
on the costs and benefits of young people’s substance misuse treatment, there are 
certain areas where evidence was unavailable, unreliable, or where there were a 
range of potential estimates for a particular input. This meant that there were 
several areas of our model where we needed to make evidence based 
assumptions. 
In Chapter 6, we explored the implication of changing two key assumptions in 
our quantitative evaluation. In particular, we have looked at sensitivities 
surrounding: 
à how the immediate benefit for young people with unplanned treatment 
exits compares to the observed reduction for those with planned 
treatment exits; and 
à how the long term benefit of reducing the number of young people 
who develop substance problems as adults varies depending on the 
choice of cost estimate. 
For the immediate benefits, we have taken the view that it would not be 
reasonable to attribute the same treatment benefit to young people who did not 
complete treatment as we observe for those who did complete treatment. 
However, it is also not reasonable to attribute no benefit of treatment to those 
with unplanned exits. Our central case estimate (which attributes half of the 
reduction achieved by young people with planned exits to those with unplanned 
exits), is therefore neither a conservative nor an optimistic assumption. 
There is more uncertainty surrounding long term benefits and as such we have 
presented our estimates as a range of values rather than point estimates. 
Estimates of the cost of adult problematic substance misuse have been sourced 
from several independent studies. Although the magnitude of the estimated cost 
implied by these studies is similar, there is no single accepted figure for the cost 
of an adult problematic drug or alcohol user. 
Although we have only directly tested the sensitivity of our results to these two 
assumptions, there are other areas of our quantitative evaluation where we have 
made evidence based assumptions that may affect our estimates. When we have 
needed to make an assumption, we have preferred to take a conservative 
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approach. Table 45 provides a list of these conservative assumptions, and the 
benefits to which they relate. The benefits we calculate can therefore be thought 
of as a conservative estimate of total benefits. 
Table 45. Description of conservative assumptions 
Description of benefit Assumptions leading to lower benefits 
Counterfactual number of assaults 
Counterfactual number of thefts 
If a young person has committed a theft or an 
assault, they did so only once per month 
Number of drug and alcohol 
related illnesses 
Number of drug and alcohol 
related deaths 
Only illness or death that can be wholly 
attributed to drug or alcohol misuse is 
included in our estimates of the immediate 
health benefits 
5% of young people using Class A drugs will 
not become adult problematic drug users if 
not treated 
Number of adult problematic Class 
A drug users 
1% of young cannabis users will become 
problematic Class A drug users as adults 
Cost of adult problematic drug use If in employment, drug users would earn the 
minimum wage 
Source: Frontier analysis 
Other assumptions we have made will neither over nor understate the size of our 
benefits estimates. For example, we assume that the level of crime committed by 
young people when they enter treatment is a good proxy for the level of crime 
they will commit up until the point that they turn 18. Crime rates vary by age. 
However, since young people typically enter treatment at age 16-17 and the crime 
rate at this age broadly reflects the level of crime committed by all young people, 
this should not bias upwards or downwards our estimates of the counterfactual 
cost of crime. 
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Annexe 1: 
The National Drug Treatment Monitoring System (“NDTMS”) records 
demographic information and other characteristics of young people entering 
treatment. In addition, young people are asked about their drug use, health, 
education, criminal behaviour and housing need at a series of points during their 
treatment. This data is then combined to create a treatment outcomes profile 
(TOP) for an individual during their progression through treatment, 
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Selected demographic information recorded in the NDTMS 
Table 46. Selected data recorded by the NDTMS 
Item Description 
Sex of client The sex that the client was at birth 
Ethnicity The ethnicity that the client states as defined in the OPCS census 
categories. If a client declines to answer then ‘not stated’ should be 
used, if a client is not asked then the field should be left blank. 
DAT of 
residence 
The Drug Action Team (or partnership area) in which the client 
normally resides (as defined by their postcode of their normal 
residence). 
PCT of 
residence 
The Primary Care Trust in which the client normally resides (as 
defined by their postcode of their normal residence). Due to DATs in 
some instances spanning many PCTs. 
Problem 
Substance 
No. 1 
The substance that brought the client into treatment at the point of 
triage/initial assessment, even if they are no longer actively using this 
substance. If a client presents with more than one substance the 
agency is responsible for clinically deciding which substance is 
primary. 
Age of first 
use of 
Problem 
Substance 
No. 1 
The Age (in years) that the client recalls first using the Problem 
Substance No. 1 
Problem 
Substance 
No. 2 
An additional substance that brought the client into treatment at the 
point of triage/initial assessment, even if they are no longer actively 
using this substance. ‘Poly drug’ should no longer be used in this 
field; instead the specific substances should be recorded in each of 
the problem substance fields. 
Problem 
Substance 
No. 3 
An additional substance that brought the client into treatment at the 
point of triage/initial assessment, even if they are no longer actively 
using this substance. ‘Poly drug’ should no longer be used in this 
field; instead the specific substances should be recorded in each of 
the problem substance fields. 
Referral 
Source 
The source or method by which a client was referred for this 
treatment episode. A valid referral source code should be used as 
defined in the NDTMS Data Set - Reference Data [3]. From April 
2008, all referral source codes are specifically for young people’s 
services and codes have been reviewed and refined. Services 
reporting to the NDTMS Young People’s Data Set should select the 
code which best reflects the referral source from the entire list of 
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codes available for this item. See APPENDIX D APPENDIX D. 
Injecting 
Status 
Is the client currently injecting, have they ever previously injected or 
never injected? 
Housing 
need 
The accommodation need refers to the current situation (28 days 
prior to treatment start) of the client with respect to housing need. 
Children How many children live with the client at least part of the time? A 
child is a person who is under the age of 18. Young people who are 
under the age of 18 years can also have parental status and should 
be asked about parental status. 
Pregnant Is the client pregnant? All sexually active young women who are 
under the age of 16 years should also be asked about pregnancy. 
Drinking days Number of days in the 28 days prior to initial assessment that the 
client consumed alcohol. 
Units of 
alcohol 
Typical number of units consumed on a drinking day in the 28 days 
prior to initial assessment 
Discharge 
date 
The date that the client was discharged ending the current structured 
(Tier 3/Tier 4) treatment episode. If a client has had a planned 
discharge then the date agreed within this plan should be used. If a 
client’s discharge was unplanned then the date of last face to face 
contact with the treatment provider should be used. 
Discharge 
reason 
The reason why the client’s episode of structured (Tier 3/Tier 4) 
treatment was ended. 
Discharge 
destination 
The lead agency that the treatment provider has referred a young 
person back or onto once the treatment episode has been 
completed. 
Source: NTA: “NDTMS Data Set: Business Definition for Young People’s Treatment Providers”, March 
1999 
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Data collected as part of the Treatment Outcomes Profile 
Table 47. Data collected by the NTA in the Treatment Outcomes Profile dataset 
Item Description 
Treatment 
Outcomes 
Profile (TOP) 
date 
Date of most recent care plan review. All outcome status 
submitted in this section of the data - set will be associated and 
stored as being the status as of this date. Note: TOP data should 
only be collected for young people aged 16 and over. 
TOP ID A technical identifier representing the TOP, as held on the clinical 
system used at the treatment provider. (NB: this should be a 
technical item, and should not hold or be composed of attributers 
which might identify the individual – this data is merely to assist in 
synchronising the data held in NDTMS with that on the clinical 
system). A possible implementation of this might be the row 
number of the TOP in the TOP table. 
Treatment 
Stage 
Stage of treatment that the TOP data relates to 
Alcohol use Number of days in previous 28 days that client has consumed 
alcohol 
Opiate use Number of days in previous 28 days that client has used opiates 
Crack use Number of days in previous 28 days that client has used crack 
Cocaine use Number of days in previous 28 days that client has used powder 
cocaine 
Amphetamine 
use 
Number of days in previous 28 days that client has used 
amphetamines 
Cannabis use Number of days in previous 28 days that client has used cannabis 
Other drug use Number of days in previous 28 days that client has used other 
problem drug 
IV drug use Number of days in previous 28 days that client has injected non 
prescribed drugs 
Sharing Has client shared needles or paraphernalia in last 28 days? 
Shop theft Number of days in previous 28 days that client has been involved 
in shop theft 
Drug selling Number of days in previous 28 days that client has been involved 
in selling drugs 
110  
 
Annexe 1:  
 
Other theft Has client has been involved in theft from or of vehicle, property or 
been involved in fraud in last 28 days 
Assault/violence Has client committed assault/violence in last 28 days 
Psychological 
health status 
Self reported score of 0 - 20 
Paid work Number of days in previous 28 days that client has had paid work 
Education Number of days in previous 28 days that client has attended 
college/education system 
Acute housing 
problem 
Has client had acute housing problem (been homeless) in last 28 
days 
Housing risk Has client been at risk of eviction within past 28 days 
Physical health 
status 
Self reported score of 0 - 20. 
Quality of Life Self reported score of 0 - 20. 
Source: NTA: “NDTMS Data Set: Business Definition for Young People’s Treatment Providers”, March 
1999 
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